KOL | Hiroshi FujishimaDepartment of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, fujishima117@gmail.com | Department of Ophthalmology, Keio University ... |
KOL Resume for Hiroshi Fujishima
| Year | |
|---|---|
| 2021 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, Ophthalmology, Tsurumi University Dental Hospital, Yokohama, Kanagawa, Japan |
| 2020 | Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-0016, Japan;, (E.S.);, (N.A.);, (Y.O.) Fujishima Eye Clinic, Niigata 949-6600, Japan |
| 2019 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Tsurumi-ku 230-8501, Kanagawa, Japan;, (N.K.);, (A.S.);, (H.F.) Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2016 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan |
| 2015 | From the *Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa; and †Department of Ophthalmology, Tokyo Saiseikai Central Hospital; and ‡J&J Ocular Surface and Visual Optics Department, Keio University School of Medicine, Tokyo, Japan. |
| 2014 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2012 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa |
| 2011 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan. |
| 2010 | Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
| 2009 | Department of Ophthalmology, Keio University, Tokyo, Japan. |
| 2008 | Department of Ophthalmology, International University of Welfare, Mita Hospital, Tokyo, Japan |
| 2007 | International University of Health and Welfare, Department of Ophthalmology, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan. |
| 2006 | From the *Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan; †Keio University School of Medicine, Tokyo, Japan; and ‡Hara Eye Clinic, Otawara, Tochigi Prefecture, Japan. Department of Ophthalmology, Keio University School of Medicine |
| 2005 | From the Department of Ophthalmology, Keio University, Tokyo, Japan; the Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13, Ichikawa, Chiba 272-8513, Japan |
| 2004 | From the Departments of *Ophthalmology and †Dermatology, Tokyo Dental College, Ichikawa, Chiba, Japan. Department of Ophthalmology, Keio University, Tokyo, Japan |
| 2003 | Department of Ophthalmology, Tokyo Dental College, Chiba, Japan |
| 2002 | Department of Ophthalmology, Tokyo Dental College, Sugano, Ichikawa, Japan. |
| 2001 | From the Departments of Ophthalmology (N.A-K., K.F., K.T., K.U., H.F.) and Dermatology (S.T.), Tokyo Dental College, Chiba, Japan. |
| 1998 | Department of Ophthalmology, Tokyo Dental College, Ichikawa, Chiba, Japan. |
| 1997 | Department of Ophthalmology, Tokyo Dental College, Chiba |
| 1996 | Department of Ophthalmology, Tokyo Dental College; Department of Ophthalmology, Keio University School of Medicine |
| 1995 | Chiba, Tokyo, and Akita, Japan Department of Ophthalmology Tokyo Dental College, Chiba |
| 1994 | Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan. |
Hiroshi Fujishima: Influence Statistics
Open the FULL List in Excel
| Concept | World rank |
|---|---|
| prostaglandin tears | #1 |
| keratoconjunctivitis akc | #1 |
| patients severe conjunctivitis | #1 |
| artificial tears positive | #1 |
| eyewash solutions bak | #1 |
| incubated interleukin | #1 |
| cd3 cd4bearing cells | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| conjunctivitis aims | #1 |
| clinical signs akc | #1 |
| eyebon | #1 |
| tacrolimus eye drops | #1 |
| allergic docosahexaenoic | #1 |
| postoperative conjunctivitis | #1 |
| vkc akc | #1 |
| conjunctival fibroblasts production | #1 |
| ded anti | #1 |
| vkc cases | #1 |
| patients capilia | #1 |
| tranilast eotaxin1 | #1 |
| conjunctivitis concomitantly | #1 |
| adenovirus capilia | #1 |
| allergic conjunctivitis efficacy | #1 |
| instillation bromfenac | #1 |
| tranilast production | #1 |
| exacerbation vkc | #1 |
| fml dscg | #1 |
| patients akc | #1 |
| fml 002 | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| conjunctivitis treated | #1 |
| patients allergic conjunctivitis | #1 |
| pge2 human conjunctival | #1 |
| 01 tacrolimus eye | #1 |
| bromfenac sodium | #1 |
| akc methods | #1 |
| dha western blotting | #1 |
| adeno eye | #1 |
| tacrolimus tears | #1 |
| eye allerwatch | #1 |
| drops elicited | #1 |
| allerwatch higher | #1 |
| bak epithelium disorders | #1 |
| rsv conjunctival | #1 |
| akc administration | #1 |
| characterized conjunctival | #1 |
| dscg symptoms | #1 |
| ketotifen fumarate dexamethasone | #1 |
| il4 causing | #1 |
| akc vernal | #1 |
| itchy sensation | #1 |
| tacrolimus eye drop | #1 |
| severe binocular conjunctivitis | #1 |
| 10 objective signs | #1 |
| commercial eyewash | #1 |
| allergic conjunctivitis drop | #1 |
| akc tear | #1 |
| accuracy conjunctivitis | #1 |
| allergic enzyme | #1 |
| radioimmunoassay il4 | #1 |
| eyewash solution bak | #1 |
| commercial eyewash solutions | #1 |
| fourgraded severity | #1 |
| higher capilia | #1 |
| conjunctival fibroblasts | #1 |
| atopic keratoconjunctivitis akc | #1 |
| selective chemotactic effects | #1 |
| fumarate dexamethasone | #1 |
| rapid ophthalmic | #1 |
| eyebon eye | #1 |
| include conjunctival | #1 |
| conjunctivitis conjunctival | #1 |
| severity objective signs | #1 |
| primary human conjunctival | #1 |
| bf fml | #1 |
| allergic corneal | #1 |
| objective findings conclusions | #1 |
| scores hyperemia | #1 |
| dha il4 | #1 |
| keratocytes tnfα | #1 |
| iop akc | #1 |
| epithelium disorders | #1 |
| eotaxin1 production | #1 |
| akc allergic | #1 |
| allergens levocabastine | #1 |
| selected fml | #1 |
| scleritis tacrolimus | #1 |
| nsaids systemic control | #1 |
| rate allerwatch | #1 |
| levocabastine artificial tears | #1 |
| tacrolimus ophthalmic solution | #1 |
| tacrolimus ophthalmic | #1 |
| conjunctival cedar | #1 |
| conclusions objective assessments | #1 |
| tears allergic patients | #1 |
| keratoconjunctivitis vernal | #1 |
| conjunctivitis including | #1 |
| pcr eotaxin1 | #1 |
| conjunctivitis enrolled | #1 |
| il4 tranilast | #1 |
| cedrus conjunctivitis | #1 |
| improvement combinedtreatment | #1 |
| production conjunctival fibroblasts | #1 |
| 01 ophthalmic solution | #1 |
| release inhibitor purpose | #1 |
| corneal epithelium disorders | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| keratoconjunctivitis background | #1 |
| systemic control pain | #1 |
| adverse events scores | #1 |
| atopic keratoconjunctivitis | #1 |
| patients atopic keratoconjunctivitis | #1 |
| tacrolimus eye | #1 |
| production tranilast | #1 |
| cox2 conjunctival | #1 |
| conjunctivitis seasonal | #1 |
| ocular allergic diseases | #1 |
| samples allergic conjunctivitis | #1 |
| fml administered | #1 |
| inhibition eotaxin1 | #1 |
| action child conjunctivitis | #1 |
| allerwatch tests | #1 |
| suspension treating | #1 |
| eyewash solution | #1 |
| binocular conjunctivitis | #1 |
| sodium allergic | #1 |
| 0001 allerwatch | #1 |
| commercial washing solution | #1 |
| immunocytochemical study rtpcr | #1 |
| eye fml | #1 |
| tears allergic | #1 |
| capilia adeno | #1 |
| allergic tranilast | #1 |
| solution allergic | #1 |
| severe conjunctivitis eyes | #1 |
| fluorometholone 002 | #1 |
| il4 tear | #1 |
| 3 months signs | #1 |
| 12 patients akc | #1 |
| hyperemia pain | #1 |
| concomitant bf | #1 |
| eye surface years | #1 |
| talymus | #1 |
| washing allergens | #1 |
| initiation tacrolimus treatment | #1 |
| conjunctivitis helper | #1 |
| drop levocabastine | #1 |
| allergenmediated conjunctivitis | #1 |
| itching levocabastine | #1 |
| eyewash solutions | #1 |
| dscg bf | #1 |
| dscg 005 | #1 |
| solution ocular | #1 |
| conjunctivitis japanese | #1 |
| bf concomitantly | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| ige allerwatch | #1 |
| allergic postoperative | #1 |
| levocabastine artificial | #1 |
| capilia adeno eye | #1 |
| tacrolimus eye treatment | #1 |
| allerwatch positivity rate | #1 |
| keratoconjunctivitis male | #1 |
| sodium bf | #1 |
| instillation symptoms | #1 |
| tacrolimus ophthalmic suspension | #1 |
| bromfenac sodium bf | #1 |
| cases severe conjunctivitis | #1 |
| akc compared | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| severe akc | #1 |
| compared fluorometholone | #1 |
| akc patients | #1 |
| adult cedrus conjunctivitis | #1 |
| child conjunctivitis | #1 |
| allergic conjunctivitis | #1 |
| eye itching | #1 |
| akc | #1 |
| antagonists child conjunctivitis | #1 |
| efficacy fml | #1 |
| fml patients | #1 |
| experience 01 | #1 |
| therapy levocabastine | #1 |
| akc treatment | #1 |
| bromobenzenes conjunctivitis | #1 |
| efficacy bromfenac sodium | #1 |
| signs palpebral | #1 |
| eyewash | #1 |
| tears conjunctival fibroblasts | #1 |
| allerwatch diagnostic accuracy | #1 |
| suppressing pge2 production | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| initiating tacrolimus | #1 |
| hundredandseventy eyes | #1 |
| bak epithelium | #1 |
| higher akc | #1 |
| subjective ocular symptoms | #1 |
| bromfenac sodium treatment | #1 |
| test capilia | #1 |
| tranilast dexamethasone | #1 |
| vkc april | #1 |
| positivity rate allerwatch | #1 |
| stat6results | #1 |
| dscg fml | #1 |
| vkc conclusions | #1 |
| eye wash | #1 |
| satisfaction suspensions | #1 |
| sodium ophthalmic solution | #1 |
| production ketotifen fumarate | #1 |
| diseases tear | #1 |
| akc vkc | #1 |
| epithelial pge2 | #1 |
| corneal findings | #2 |
| total signs symptoms | #2 |
| detected akc | #2 |
| tacrolimus shield | #2 |
| papillae mucous discharge | #2 |
| vkc japan | #2 |
| akc patients correlation | #2 |
| score adjustments | #2 |
| ecp severity markers | #2 |
| diagnosis ensured | #2 |
| patients severe akc | #2 |
| resolution thermography | #2 |
| nonpreserved eyewash solution | #2 |
| complain foreign | #2 |
| air pollutants prevalence | #2 |
| environmental studies prevalence | #2 |
| disease antiallergic | #2 |
| cytodiagnosis dermatitis | #2 |
| nonwash | #2 |
| oral ari | #2 |
| tacrolimus detection | #2 |
| mucin analyzed | #2 |
| tacrolimus tonometry | #2 |
| administration specular | #2 |
| skin elasticity patients | #2 |
| eyewash 005 | #2 |
| signs decreased | #2 |
| iop topical steroids | #2 |
| post cataract surgery | #2 |
| giant papillae formation | #2 |
| 95 adjuvant betamethasone | #2 |
| score topical | #2 |
| epinastine ophthalmic solution | #2 |
| asthma heart diseases | #2 |
| eyelid elasticity | #2 |
| tacrolimus iop | #2 |
| keratoconjunctivitis corneal | #2 |
| akc 10 eyes | #2 |
| akc adolescent | #2 |
| akc sac patients | #2 |
| patients corneal ulcers | #2 |
| allergic conjunctivitis levocabastine | #2 |
| bromfenac ophthalmic solution | #2 |
| japan topical tacrolimus | #2 |
| effects topical tacrolimus | #2 |
| accompanied subjective | #2 |
| conjunctival injection edema | #2 |
| cutometer sem575 | #2 |
| conjunctival corneal cells | #2 |
| premedication combined | #2 |
| corneal temperature patients | #2 |
| representative subjective | #2 |
| factor vkc | #2 |
| tarsal brush | #2 |
| atopic blepharitis | #2 |
| excision cobblestone | #2 |
| ceramide gel application | #2 |
| conjunctival injection reduction | #2 |
| solutions japan | #2 |
| elevation tacrolimus | #2 |
| edema height | #2 |
| serum allergic parameters | #2 |
| topical antiallergic agents | #2 |
| dermatitis remission | #2 |
| normal blinking patients | #2 |
| allergy accompanied | #2 |
| fluorescein conjunctival injection | #2 |
| improvement vital staining | #2 |
| lesions allergic | #2 |
| refractory allergic | #2 |
| bovine entericcoated lactoferrin | #2 |
| regrowth 7 eyes | #2 |
| betamethasone glaucoma | #2 |
| drop steroid | #2 |
| japan topical | #2 |
| conjunctivitis 10 | #2 |
| conjunctivitis epitheliopathy | #2 |
| corneal damage patients | #2 |
| recurrence corneal lesions | #2 |
| 18 akc | #2 |
| tears thiazolidines | #2 |
| superiority epinastine | #2 |
| treatment shield ulcer | #2 |
| administered elf | #2 |
| patients shield | #2 |
| cornea grading | #2 |
| conjunctival findings severity | #2 |
| bromfenac effective | #2 |
| papillae preventing | #2 |
| regrowth papillae | #2 |
| elasticity eyelid | #2 |
| conclusions bromfenac | #2 |
| conjunctiva papillary | #2 |
| lower conjunctival sacs | #2 |
| akc treated | #2 |
| tacrolimus 1 month | #2 |
| improvement corneal fluorescein | #2 |
| prevalence akc | #2 |
| akc allergic diagnosis | #2 |
| tear ige correlation | #2 |
| giant papillary formation | #2 |
| cedrus conjunctiva | #2 |
| elasticity severity | #2 |
| 062 tear | #2 |
| endpoint itching scale | #2 |
| aureussecreted enterotoxins | #2 |
| corneal lesions | #2 |
| tear film layer | #2 |
| treatment tear | #2 |
| proliferative called | #2 |
| concomitantly abovementioned | #2 |
| drops hyperemia | #2 |
| oral ari ono2235 | #2 |
| allergic conjunctivitis akc | #2 |
| sem575 quantitatively | #2 |
| oral ari administration | #2 |
| deqs tear | #2 |
| edema corneal damage | #2 |
| treatment total signs | #2 |
| aided papillary | #2 |
| correlation neutrophils | #2 |
| sac healthy | #2 |
| adjuvant betamethasone | #2 |
| cac test | #2 |
| oral aldose | #2 |
| conjunctiva atopic | #2 |
| mmc 7 eyes | #2 |
| noninferiority olopatadine | #2 |
| conventional antiallergic drugs | #2 |
| talymus akc | #2 |
| rhodanine rose | #2 |
| folliculosis papillae | #2 |
| study designopen cohort | #2 |
| baseline papillae | #2 |
| recurrence corneal complications | #2 |
| akc levels | #2 |
| lessen steroid | #2 |
| benzophenones bromobenzenes | #2 |
| allergic conjunctivitis ige | #2 |
| lactoferrin 01 | #2 |
| mucous discharge severity | #2 |
| epitheliopathy corneal | #2 |
| corneal complications height | #2 |
| solution epinastine | #2 |
| tacrolimus published data | #2 |
| eyes betamethasone | #2 |
| akc 6 | #2 |
| severity eyelid | #2 |
| japan akc | #2 |
| scores tacrolimus | #2 |
| tacrolimus lessen | #2 |
| placebo noninferiority | #2 |
| pge2 tears | #2 |
| tacrolimus topical | #2 |
| tears akc | #2 |
| bromfenac sodium bromfenac | #2 |
| conjunctivitis retrospective | #2 |
| month eyewash | #2 |
| severity corneal complications | #2 |
| conjunctivitis representative | #2 |
| corneal lesions regrowth | #2 |
| patients shield ulcers | #2 |
| drops refractory | #2 |
| female humans akc | #2 |
| epitheliopathy steroids | #2 |
| pollutants prevalence | #2 |
| ophthalmic nsaid | #2 |
| akc 1 | #2 |
| steroid metaregression | #2 |
| suspension talymus | #2 |
| conjunctivitis purpose | #2 |
| excision cobblestonelike papillae | #2 |
| bovine placebo | #2 |
| blepharitis ceramides | #2 |
| corneal ulcers patients | #2 |
| conjunctivitis condition | #2 |
| correlation eosinophils | #2 |
| seasonal allergic conjunctivitis | #2 |
| correlation fluorescein | #2 |
| drop concomitantly | #2 |
| ketotifen dexamethasone | #2 |
| epitheliopathy refractory | #2 |
| signs blood concentration | #2 |
| ensured proving | #2 |
| sem575 | #2 |
| eyes 824 | #2 |
| based papillae | #2 |
| suspension lactoferrin | #2 |
| 2helper cell | #2 |
| papillary excision | #2 |
| methods thirtysix patients | #2 |
| lacrimation objective | #2 |
| tacrolimus 12 weeks | #2 |
| simple papillary resection | #2 |
| simple resection regrowth | #2 |
| epitheliopathy score | #2 |
| limbal swelling | #2 |
| extents corneal | #2 |
| corneal epitheliopathy score | #2 |
| sem575 clinical | #2 |
| unpaired ttest talymus | #2 |
| akc 10 | #2 |
| conjunctivitis adolescent | #2 |
| ocular surface mucin | #2 |
| brush cytology patients | #2 |
| height papillae | #2 |
| corneal damage height | #2 |
| allergic diagnosis | #2 |
| adjustments epitheliopathy | #2 |
| diathesis subjective | #2 |
| olopatadine visit | #2 |
| epinastine superiority | #2 |
| objective signs baseline | #2 |
| including akc | #2 |
| akc young adult | #2 |
| dryness scores | #2 |
| diabetic patients ono2235 | #2 |
| epitheliopathy patients | #2 |
| topical tacrolimus combination | #2 |
| tacrolimus detection limit | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| control subjects eyes | #2 |
| period rhodanine | #2 |
| total clinical signs | #2 |
| metaregression analysis glaucoma | #2 |
| corneal epitheliopathy | #2 |
| decrease corneal temperature | #2 |
| keratoconjunctivitis age | #2 |
| olopatadine cedar | #2 |
| administered elf bovine | #2 |
| mmc aided | #2 |
| eyelid atopic | #2 |
| papillae severe | #2 |
| patients tacrolimus eye | #2 |
| sodium bromfenac | #2 |
| neutrophils brush | #2 |
| brush cytology samples | #2 |
| sodium ophthalmic | #2 |
| olopatadine ocular | #2 |
| ulcer complain | #2 |
| atopic diagnostic techniques | #2 |
| corneal epithelial signs | #2 |
| vkc 5 | #2 |
| adjustments epitheliopathy score | #2 |
| drops conjunctival | #2 |
| immunoregulatory effects study | #2 |
| adjuvant fluorometholone | #2 |
| neutrophils corneal damage | #2 |
| conjunctivitis proliferative | #2 |
| papilla accompanied | #2 |
| formation akc | #2 |
| hyperemia lacrimation | #2 |
| reported eotaxin | #2 |
| papillae akc | #2 |
| akc adult | #2 |
| lid skin | #2 |
| csa akc | #2 |
| severity corneal damage | #2 |
| akc aureus | #2 |
| cobblestonelike papillae | #2 |
| adjuvant fluorometholone 95 | #2 |
| scores papillary | #2 |
| treatment ecp concentrations | #2 |
| conjunctiva bulbar | #2 |
| treated bromfenac | #2 |
| inflammatory child child | #2 |
| epinastine 15 minutes | #2 |
| evaluate superiority | #2 |
| selected bf | #2 |
| defined conjunctival | #2 |
| 001 brush | #2 |
| shield ulcers patients | #2 |
| effects tacrolimus | #2 |
| severe allergic conjunctivitis | #2 |
| ecp levels akc | #2 |
| ari ocular | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| largescale study protocol | #2 |
| papillary formation | #2 |
| test papillae | #2 |
| severity corneal lesions | #2 |
| production specular | #2 |
| epitheliopathy shield | #2 |
| 1 month tacrolimus | #2 |
| papillae limbus | #2 |
| corneal recurrences | #2 |
| plaques 791 | #2 |
| efficacy severe akc | #2 |
| eyelid atopic dermatitis | #2 |
| eosinophils corneal damage | #2 |
| muc16 immunohistochemistry | #2 |
| eyelid skin elasticity | #2 |
| swelling folliculosis | #2 |
| formation palpebral | #2 |
| allergic endophthalmitis | #2 |
| steroids epitheliopathy | #2 |
| treatment atopic blepharitis | #2 |
| tear il13 | #3 |
| evaluate tear | #3 |
| nbs normal eyes | #3 |
| corneal epithelial structure | #3 |
| vkc sac | #3 |
| eyes control subjects | #3 |
| formation vkc | #3 |
| conjunctivitis allergic | #3 |
| outpatient attendance july | #3 |
| tears treatment | #3 |
| 005 mmc | #3 |
| sde controls | #3 |
| flare metry | #3 |
| 5ac mrna | #3 |
| techniques conjunctivitis | #3 |
| conjunctivitis pm25 | #3 |
| cholinergic treatment response | #3 |
| corneal complications1 | #3 |
| allergic postsurgical | #3 |
| akc atopic dermatitis | #3 |
| akc eyes | #3 |
| eye washing | #3 |
| higher muc1 eyes | #3 |
| induced inflammation lenses | #3 |
| superior limbic portion | #3 |
| dry eye eye | #3 |
| dibenzoxepins female | #3 |
| patching case | #3 |
| outpatient visits august | #3 |
| increased comfort | #3 |
| healing allergic | #3 |
| thermography evaluate | #3 |
| hyperemia allergic | #3 |
| akc persistent | #3 |
| vkc cell | #3 |
| strip meniscometry testing | #3 |
| ecp severity | #3 |
| permeability postoperatively | #3 |
| ari corneal | #3 |
| pm25 outpatient attendance | #3 |
| aureus akc patients | #3 |
| normal controls collagens | #3 |
| akc higher | #3 |
| treatment skin elasticity | #3 |
| periostin akc | #3 |
| treatment strip meniscometry | #3 |
| mmc authors | #3 |
| laser cellflaremetry | #3 |
| severe allergic patients | #3 |
| cell flare count | #3 |
| histamine conjunctival cells | #3 |
| aged elisa | #3 |
| oct graticule | #3 |
| solutions prospective | #3 |
| akc serum periostin | #3 |
| allergic corneal diseases | #3 |
| insensible administration insensible | #3 |
| tissue remodeling exacerbation | #3 |
| papillae upper | #3 |
| infrared radiation thermography | #3 |
| oct tmh | #3 |
| fluorescein scale | #3 |
| eyes allergic | #3 |
| july pm25 | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| cooling cataract | #3 |
| pilocarpine visante | #3 |
| allergic corneal ulcer | #3 |
| ulcer persistent | #3 |
| akc biomarkers | #3 |
| vivo corneal akc | #3 |
| underwent periodic | #3 |
| conjunctivitis benzamidines | #3 |
| il1beta th2 cytokines | #3 |
| scored global | #3 |
| commercial washing | #3 |
| diclofenac epithelium | #3 |
| differences dfna | #3 |
| phenomena tacrolimus | #3 |
| signs remission | #3 |
| eyes akc | #3 |
| 1 month initiation | #3 |
| par2 benzamidines blotting | #3 |
| superficial cells conjunctiva | #3 |
| surgery dfna | #3 |
| aged biological dressings | #3 |
| akc confocal microscopy | #3 |
| conjunctival disease | #3 |
| local tear deficiency | #3 |
| healing dramatic healing | #3 |
| 01 ophthalmic | #3 |
| vkc 5 eyes | #3 |
| diseases acds | #3 |
| allergic patients conjunctivitis | #3 |
| 21 akc patients | #3 |
| vkc long | #3 |
| alterations tear | #3 |
| dfna diclofenac epithelium | #3 |
| relevant factor exacerbation | #3 |
| diabetic corneal disease | #3 |
| portable recordable | #3 |
| antibody titers ade | #3 |
| topical cyclosporine 01 | #3 |
| periostin comorbidities | #3 |
| outpatient visits july | #3 |
| study cutometer | #3 |
| tear periostin | #3 |
| histamine superficial cells | #3 |
| rose bengal akc | #3 |
| immunosuppressive eye | #3 |
| injections keratoconjunctivitis | #3 |
| dramatic healing | #3 |
| traumatic swelling | #3 |
| 22 eyes 100 | #3 |
| cells brush cytology | #3 |
| improvement squamous metaplasia | #3 |
| titers ade | #3 |
| akc tear periostin | #3 |
| fibronectin normal controls | #3 |
| laser flarecellmetry | #3 |
| cultured tryptase | #3 |
| protein conjunctival fibroblasts | #3 |
| nuclei vkc | #3 |
| keratoconjunctivitis leupeptins | #3 |
| vkc exacerbation | #3 |
| 3 sjögrens syndrome | #3 |
| lnfs nbs | #3 |
| epithelium adverse | #3 |
| uncontrollable glaucoma | #3 |
| il1beta th2 | #3 |
| vkc relevant factor | #3 |
| fibers lnfs | #3 |
| scale tmh | #3 |
| formation vernal | #3 |
| vkc eyes | #3 |
| akc rose bengal | #3 |
| vkc levels | #3 |
| tryptase conjunctiva | #3 |
| insufficient tear | #3 |
| 111 177 | #3 |
| fibronectin vkc | #3 |
| technique uncontrollable | #3 |
| adedry eye | #3 |
| technique 2 eyes | #3 |
| drops treat | #3 |
| pretreatment docosahexaenoic acid | #3 |
| mmc excision | #3 |
| tmh measurement | #3 |
| tryptase increases | #3 |
| antieaigg | #3 |
| treatment vernal | #3 |
| akc comorbidities | #3 |
| central corneal temperature | #3 |
| akc periostin | #3 |
| techniques tears | #3 |
| papillary regrowth | #3 |
| benzamidine par2 | #3 |
| allergic cornea | #3 |
| eye cooling | #3 |
| dfna eye | #3 |
| interleukin4 tacrolimus | #3 |
| temperature evaluate | #3 |
| 21 akc | #3 |
| akc confocal | #3 |
| 12 akc | #3 |
| efficacy bromfenac | #3 |
| child conjunctiva | #3 |
| dfna control | #3 |
| corneal akc | #3 |
| association outpatient attendance | #3 |
| 12 akc patients | #3 |
| dfna eye dfna | #3 |
| weekly average values | #3 |
| hydrochloride 01 | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| histamine cedar pollen | #3 |
| pollen august | #3 |
| periostin topical | #3 |
| macroerosions | #3 |
| pollen postoperative | #3 |
| vkc papillae | #3 |
| ophthalmic solution nsaid | #3 |
| cases vkc | #3 |
| ophthalmic solution placebo | #3 |
| par2 cultured | #3 |
| 13 eyes 69 | #3 |
| allerwatch | #3 |
| ebv ade | #3 |
| keratoconjunctivitis vkc | #3 |
| diclofenac eye drops | #3 |
| cytology impression | #3 |
| tear periostin patients | #3 |
| corneal ulceration role | #3 |
| pm25 allergic | #3 |
| akc dyes humans | #3 |
| elisa histamine | #3 |
| samples correlate | #3 |
| conjunctival fibroblasts tryptase | #3 |
| inflammation mmc | #3 |
| glaucoma amniotic | #3 |
| epinastine placebo | #3 |
| proving type | #3 |
| tear periostin biomarker | #3 |
| lamp device | #3 |
| eosinophils corneal | #3 |
| ulcer akc | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| sdedry eye | #3 |
| antiallergic eye drop | #3 |
| akc alterations | #3 |
| akc higher muc1 | #3 |
| 5 eyes akc | #3 |
| ulcers eyes | #3 |
| lacrimal punctal occlusion | #3 |
| decline corneal | #3 |
| conjunctivitis lymphocytes | #3 |
| treatment oral pilocarpine | #3 |
| ulcers plaques | #3 |
| autumnal pollen | #3 |
| lower muc5ac | #3 |
| eyes vkc | #3 |
| muc1 brush cytology | #3 |
| cornea atopic | #3 |
| existence par2 mrna | #3 |
| 005 collagens | #3 |
| cell metry | #3 |
| conjunctival corneal | #3 |
| patients tmh measurements | #3 |
| icecold eye mask | #3 |
| measurements schirmer | #3 |
| production conjunctival | #3 |
| operation eye | #3 |
| healed amniotic | #3 |
| underwent staining | #3 |
| ssdry | #3 |
| superior keratoconjunctiva | #3 |
| papillary resection | #3 |
| giant papilla | #3 |
| ocular surface diabetes | #3 |
| vkc fibronectin | #3 |
| 5ac brush | #3 |
| conjunctivitis negative | #3 |
| 01 bromfenac | #3 |
| severe allergy patients | #3 |
| patients pilocarpine tablets | #3 |
| histamine specimens | #3 |
| nonpreserved artificial tears | #3 |
| rtpcr par2 | #3 |
| drop selected | #3 |
| interleukin4 histamine | #3 |
| tears adolescent | #3 |
| conjunctiva allergic | #3 |
| fluorescein glycyrrhizic | #3 |
| erosions refractory | #3 |
| patching patient | #3 |
| sligkv examined | #3 |
| nbs subbasal | #3 |
| insufficient tear supply | #3 |
| prophylaxis conjunctival | #3 |
| postsurgical conjunctivitis | #3 |
| existence par2 | #3 |
| vkc differences | #3 |
| allergic conjunctivitis aged | #3 |
| tear periostin comorbidities | #3 |
| metry dfna | #3 |
| cases vernal | #3 |
| dscg administration | #3 |
| histamine cedar | #3 |
| mmcaided papillary resection | #3 |
| papillae morphometric | #3 |
| sensitivity tear | #3 |
| conjunctiva conjunctivitis | #3 |
| prospectively diclofenac | #3 |
| membrane uncontrollable | #3 |
| 005 ophthalmic solution | #3 |
| reaction conjunctiva | #3 |
| 4 chemokines stimulation | #4 |
| stimulation chemokine expression | #4 |
| oedema papillary | #4 |
| akc crth2 expression | #4 |
| ulcers atopic | #4 |
| 020 013 | #4 |
| topical oral steroids | #4 |
| chemokine genes fibroblasts | #4 |
| ophthalmologists eye drops | #4 |
| subjects muc5ac | #4 |
| levocabastine ophthalmic | #4 |
| eyes akc patients | #4 |
| membrane patching | #4 |
| conjunctiva density | #4 |
| correlation outpatient | #4 |
| alterations atopic | #4 |
| clinical conjunctival | #4 |
| cases sufficient examination | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| crth2 peripheral | #4 |
| eye operation | #4 |
| limbal grafts | #4 |
| defensins greater | #4 |
| staining muc16 | #4 |
| 2 4 alterations | #4 |
| studied corneal | #4 |
| lower tear function | #4 |
| highrisk glaucoma patients | #4 |
| tryptase dose | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| atopic vernal | #4 |
| include ocular | #4 |
| sac grade | #4 |
| akc healthy | #4 |
| primary sources chemokines | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| thermography anterior | #4 |
| greater 3 grade | #4 |
| male ophthalmic | #4 |
| infected conjunctival | #4 |
| cytometry mild cases | #4 |
| allergic cytological | #4 |
| solutions piperidines | #4 |
| cornea grading scale | #4 |
| keratoconjunctivitis purpose | #4 |
| crth2 akc | #4 |
| epithelial cells rsv | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| ophthalmologists evaluated | #4 |
| untreated asian dust | #4 |
| inflammation akc | #4 |
| placebo ophthalmic | #4 |
| ocular allergic disease | #4 |
| conjunctival papillary | #4 |
| atopic ocular allergies | #4 |
| persistent 6 | #4 |
| rejection limbal | #4 |
| epithelial pge2 production | #4 |
| vkc male receptors | #4 |
| vkc messenger reverse | #4 |
| individuals pgd2 | #4 |
| controls brush cytology | #4 |
| corneal temperature blink | #4 |
| akc rtpcr | #4 |
| staining ocular | #4 |
| epithelial muc16 | #4 |
| pathogenesis noninfectious | #4 |
| sensitization asian dust | #4 |
| vmr 3 months | #4 |
| tears patients | #4 |
| ige conjunctival | #4 |
| diseases portable | #4 |
| conjunctival proliferative | #4 |
| allergies blinding | #4 |
| histamine h1 antagonist | #4 |
| metaplasia reduction | #4 |
| rsv conjunctiva | #4 |
| completely severe | #4 |
| mucins 1 | #4 |
| aged rose | #4 |
| 2010 allergic | #4 |
| disease akc | #4 |
| formation conjunctivitis | #4 |
| interferometry grade | #4 |
| corneal sensitivity measurements | #4 |
| rose bengal scores | #4 |
| recordable slit | #4 |
| eyes insignificant | #4 |
| mucin mucins tears | #4 |
| underwent corneal | #4 |
| patient atopic keratoconjunctivitis | #4 |
| acuity akc | #4 |
| rsv allergic reaction | #4 |
| healthy individuals rtpcr | #4 |
| patients topical cyclosporine | #4 |
| excision papillary | #4 |
| treatment vmr values | #4 |
| ulcers mucin | #4 |
| implantation thinoptx | #4 |
| p0001 impression | #4 |
| corneal temperature eye | #4 |
| specimens underwent | #4 |
| patients epithelial disease | #4 |
| microscope evaluating | #4 |
| blinding purpose | #4 |
| simple resection | #4 |
| eye wash solution | #4 |
| vkc 4 | #4 |
| hypersensitivity mucin | #4 |
| 33 chemokines | #4 |
| papillae normal | #4 |
| folliculosis | #4 |
| conjunctivitis vkc | #4 |
| ulcers control subjects | #4 |
| severe ocular allergies | #4 |
| epithelial disease patients | #4 |
| defensins conjunctivitis | #4 |
| july pollen | #4 |
| temperature corneal | #4 |
| eosinophils receptor crth2 | #4 |
| portable slit | #4 |
| 0001 brush | #4 |
| akc crth2 | #4 |
| mucins tears mucin | #4 |
| steroids fluorometholone | #4 |
| cultured conjunctival | #4 |
| treatment vmr | #4 |
| special brush | #4 |
| keratoconjunctivitis lacrimal | #4 |
| bengal sensation | #4 |
| rsv conjunctival epithelium | #4 |
| drop artificial tears | #4 |
| atopic dermatitis remission | #4 |
| wilcoxon signed test | #4 |
| acds conventional | #4 |
| vkc normal controls | #4 |
| muc5ac brush cytology | #4 |
| muc5ac mrna expression | #4 |
| moisture checker | #4 |
| patient eyes fluorescein | #4 |
| proteinchip array elisa | #4 |
| deqs scores | #4 |
| topical 01 tacrolimus | #4 |
| conjunctivitis ige | #4 |
| muc1 2 | #4 |
| akc sac | #4 |
| dust wheal | #4 |
| corneal ulcers muc5ac | #4 |
| thinoptx acrysof | #4 |
| eyes ulcers | #4 |
| thinoptx lens | #4 |
| il4 tears | #4 |
| tomography tear | #4 |
| papillae giant | #4 |
| akc healthy individuals | #4 |
| lesions regrowth | #4 |
| conjunctivitis methods | #4 |
| pgd2dependent migration eosinophils | #4 |
| weeks vital | #4 |
| acds ophthalmologists | #4 |
| allergic conjunctival disease | #4 |
| fva treatment | #4 |
| akc chemotaxis | #4 |
| grade dry eye | #4 |
| tnfalpha30ng | #4 |
| interleukin2 tears | #4 |
| asian dust extract | #4 |
| samples histocytological | #4 |
| eyes epithelial disease | #4 |
| allergic conjunctival | #4 |
| implantation rollable | #4 |
| severe vkc patients | #4 |
| insignificant epithelial | #4 |
| allergic patients elisa | #4 |
| eosinophil toxic activity | #4 |
| controls interferometry | #4 |
| pcr epithelial | #4 |
| conventional portable | #4 |
| eotaxin1 rantes | #4 |
| tear function test | #4 |
| eye sjögrens syndrome | #4 |
| goblet cell muc5ac | #4 |
| giemsas staining | #4 |
| sensation tears | #4 |
| noninfectious necrotizing | #4 |
| muc16 goblet | #4 |
| compared vkc | #4 |
| corneal sensitivity measurement | #4 |
| photophobia diagnosis | #4 |
| pgd2dependent migration | #4 |
| fibroblasts primary sources | #4 |
| conjunctivitis levels | #4 |
| surface conjunctival | #4 |
| sterilized asian dust | #4 |
| assay pgd2 | #4 |
| ocular surface epithelial | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| atopic ocular | #4 |
| sac control eyes | #4 |
| 18 akc patients | #4 |
| patients severe vkc | #4 |
| adolescent betamethasone | #4 |
| par2 mrna protein | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| performed tears | #4 |
| epithelial disease eyes | #4 |
| tears pathogenesis | #4 |
| 10 seconds temperature | #4 |
| pgd2 normal volunteers | #4 |
| epithelial muc | #4 |
| insignificant epithelial disease | #4 |
| ded 1 | #4 |
| p0001 brush | #4 |
| interferometry controls | #4 |
| akcaffected patients | #4 |
| thinoptx | #4 |
| muc5ac brush | #4 |
| dscg day | #4 |
| tear temperature | #4 |
| interferometry lipids | #4 |
| allergic fibroblasts | #4 |
| samples immunocytochemical | #4 |
| interferometry 2 | #4 |
| 34 15 seconds | #4 |
| tablets tears | #4 |
| metaregression analysis effects | #4 |
| cell muc5ac | #4 |
| corneal safety | #4 |
| hydrochloride ophthalmic | #4 |
| chemotaxis conjunctiva | #4 |
| controls interferometry grade | #4 |
| allergic conjunctivitis rsv | #4 |
| diameter allergen | #4 |
| immunologic receptors akc | #4 |
| tear function patients | #4 |
| fungi epidemiologic studies | #4 |
| eyes thinoptx | #4 |
| akc immunologic receptors | #4 |
| sterilized asian | #4 |
| lower tear clearance | #4 |
| muc16 muc5ac alterations | #4 |
| surface muc5ac | #4 |
| samples allergic | #4 |
| steroids iop | #4 |
| thermometer 20 | #4 |
| thinoptx intraocular | #4 |
| muc5ac alterations | #4 |
| ari ono2235 | #4 |
| akc pgd2dependent migration | #4 |
| months papillary | #4 |
| cytometry mild | #4 |
| staining muc | #4 |
| 061 028 degree | #4 |
| levocabastine h1 | #4 |
| cytology goblet | #4 |
| tacrolimus conclusions | #4 |
| allergic conjunctival diseases | #4 |
| trantas | #4 |
| cells lnfs | #4 |
| eyes video | #4 |
| epinastine hydrochloride | #4 |
| 3004 respondents | #4 |
| sio2 20 | #4 |
| bromfenac eye drops | #4 |
| allergic epidemiologic studies | #4 |
| corneal ulcers eyes | #4 |
| genes conjunctival | #4 |
| greater concentrations tears | #4 |
| tears 10 patients | #4 |
| eyes sac | #4 |
| scores conjunctival | #4 |
| exponential equation inclination | #4 |
| bromfenac ophthalmic | #4 |
| erosion shield | #4 |
| level conjunctiva | #4 |
| eyes corneal ulcers | #4 |
| conjunctiva differences | #4 |
| akc disease | #5 |
| thinoptx iol | #5 |
| crth2 eosinophils | #5 |
| keratoconjunctivitis giant | #5 |
| treatment tacrolimus ointment | #5 |
| samples akc | #5 |
| visits august | #5 |
| regulation allergic cornea | #5 |
| ocular allergic | #5 |
| solution olopatadine | #5 |
| age 9 ± | #5 |
| akc normal subjects | #5 |
| vcam1 fibroblasts | #5 |
| ocular anesthesia | #5 |
| punctal occlusion oct | #5 |
| hne ihc | #5 |
| conjunctiva dermatitis | #5 |
| bengal suture | #5 |
| mitomycin excision | #5 |
| wilcoxonmatched pair test | #5 |
| inflammatory cells hel | #5 |
| 310±165 years | #5 |
| adolescent conjunctivitis | #5 |
| 0001 strip | #5 |
| conjunctival inflammatory status | #5 |
| conventional steroid treatment | #5 |
| study epinastine | #5 |
| stainings tear | #5 |
| allergic cyclosporine | #5 |
| severe conjunctivitis | #5 |
| controls ebv | #5 |
| warmer improved | #5 |
| cells vkc | #5 |
| upper palpebral | #5 |
| asthenopia dry | #5 |
| layer mgd | #5 |
| adhered corneal | #5 |
| labeling surface akc | #5 |
| 20 akc patients | #5 |
| allergic keratopathy | #5 |
| allergic conjunctivitis patients | #5 |
| 329±57 years | #5 |
| treatment shield | #5 |
| month tear | #5 |
| disposable eyelid | #5 |
| accompanying allergic | #5 |
| lower atopic | #5 |
| conjunctival confocal microscopy | #5 |
| postsurgical inflammation | #5 |
| diclofenac eye | #5 |
| pm25 outpatient | #5 |
| 376±56 years | #5 |
| vkc atopic | #5 |
| trantas dots | #5 |
| akc laser | #5 |
| akc acinar | #5 |
| treatment epinastine | #5 |
| warmer applied | #5 |
| prostaglandin chemotaxis | #5 |
| staining administration | #5 |
| oct lower | #5 |
| signs akc | #5 |
| scans akc | #5 |
| pretreatment dha | #5 |
| lipid oxidation hel | #5 |
| months amniotic | #5 |
| injection conjunctival | #5 |
| damage impression | #5 |
| antifungal mcfg | #5 |
| human conjunctival fibroblasts | #5 |
| conjunctival lipid | #5 |
| females akc | #5 |
| cornea cytodiagnosis | #5 |
| 15 minutes dose | #5 |
| 01 mcfg | #5 |
| hel ihc | #5 |
| cases tests | #5 |
| allergic drug therapy | #5 |
| intraoperative mitomycin excision | #5 |
| severity akc | #5 |
| conjunctivitis prostaglandin | #5 |
| eosinophils immunologic receptors | #5 |
| 7 conjunctival | #5 |
| dryeye symptoms | #5 |
| controls inflammatory cells | #5 |
| crth2 prostaglandin receptors | #5 |
| corneal fibroblasts icam1 | #5 |
| severe stevensjohnson syndrome | #5 |
| ocular surface disorder | #5 |
| akc hel | #5 |
| schiff immunohistochemical | #5 |
| il4 histamine | #5 |
| keratoconjunctivitis objective | #5 |
| disposable eyelidwarming device | #5 |
| ophthalmic suspension | #5 |
| equipment dry | #5 |
| hel akc | #5 |
| 005 schirmer1 | #5 |
| ulcer dermatitis | #5 |
| eosinophil adherence fibroblasts | #5 |
| bromobenzenes cornea | #5 |
| fibroblasts eosinophil adherence | #5 |
| inflammation mitomycin | #5 |
| conjunctiva mmc | #5 |
| damaged eosinophil | #5 |
| accompanied varying | #5 |
| corneal involvement | #5 |
| ulcers controls | #5 |
| tears received | #5 |
| pgd2 normal | #5 |
| schirmer1 test groups | #5 |
| hel cytokines | #5 |
| measurements strip | #5 |
| scores expressibility | #5 |
| eye circulating | #5 |
| treatment dryeye symptoms | #5 |
| tnfα costimulation | #5 |
| array chemotaxis | #5 |
| conjunctivitis pollen | #5 |
| mcfg eye | #5 |
| 20 sio2 | #5 |
| stained conjunctival | #5 |
| younger age effects | #5 |
| case corneal ulcer | #5 |
| histamine superficial | #5 |
| eye warmer | #5 |
| ophthalmic test | #5 |
| situ nickend regulation | #5 |
| lesion corneal | #5 |
| akc ecp | #5 |
| anterior fluorometry | #5 |
| temperature blink | #5 |
| vkc iop | #5 |
| eye warmer treatment | #5 |
| impression cytology samples | #5 |
| akc patients study | #5 |
| alpha allergic | #5 |
| alterations ocular | #5 |
| worse akc | #5 |
| impression brush | #5 |
| cornea explain | #5 |
| supernatants conjunctival | #5 |
| solutions pollen | #5 |
| thiazolidines administration | #5 |
| visits july | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| conjunctival allergen | #5 |
| staining muc5ac | #5 |
| fibroblasts fibroblast damage | #5 |
| allergic female | #5 |
| eosinophil adhesion fibroblasts | #5 |
| endophthalmitis eosinophils | #5 |
| stimulated conjunctival | #5 |
| cytokinestimulation | #5 |
| 5 females akc | #5 |
| meniscus punctal | #5 |
| 3 cases followup | #5 |
| 17 mgd patients | #5 |
| status confocal | #5 |
| disease conjunctivitis | #5 |
| diseases required | #5 |
| eosinophils activated fibroblasts | #5 |
| local tear | #5 |
| topical cyclosporine therapy | #5 |
| dryeye symptoms treatment | #5 |
| anterior scleritis patients | #5 |
| ihc conjunctival inflammation | #5 |
| simple papillary | #5 |
| conjunctival confocal | #6 |
| severe vkc | #6 |
| evaporation vital | #6 |
| il4 il2r | #6 |
| examinations tear | #6 |
| scores goblet | #6 |
| oxidation hel | #6 |
| severe stevens | #6 |
| eosinophil recruiting chemokines | #6 |
| akc vernal keratoconjunctivitis | #6 |
| female fluorometholone | #6 |
| allergens cedrus | #6 |
| hyperemia imidazoles | #6 |
| levels air pollutants | #6 |
| controlling eyelid | #6 |
| tbut vital | #6 |
| challenge cac | #6 |
| schirmer1 test values | #6 |
| specimens akc | #6 |
| conjunctival brush cytology | #6 |
| induced tear | #6 |
| signs scored | #6 |
| tear eosinophil | #6 |
| patients seldi | #6 |
| chloride eye | #6 |
| twicedaily instillation | #6 |
| july correlation | #6 |
| extract sterilized | #6 |
| coated elf | #6 |
| dfna | #6 |
| dermatitis scored | #6 |
| sac vkc | #6 |
| defect ped | #6 |
| corneal temperature | #6 |
| intolerable irritation | #6 |
| conjunctivitis sac | #6 |
| diseases periostin | #6 |
| 4 9 genes | #6 |
| allergic diathesis | #6 |
| patients visante | #6 |
| topical levocabastine | #6 |
| density conjunctival | #6 |
| 4 muc | #6 |
| ointment blood | #6 |
| corneal fibroblasts pathogenesis | #6 |
| syndrome tablets | #6 |
| functions topical | #6 |
| fluorometholone follow | #6 |
| noninvasive suction device | #6 |
| samples underwent | #6 |
| akc refractory | #6 |
| sde ade | #6 |
| conjunctival diseases | #6 |
| tryptase proliferation | #6 |
| concomitant eye | #6 |
| cyclosporine 01 | #6 |
| obstructive mgd patients | #6 |
| antiallergic eye | #6 |
| solution commercial | #6 |
| ocular fatigue | #6 |
| ade sde | #6 |
| differences tear | #6 |
| grading tear | #6 |
| hyperemia swelling | #6 |
| dust asian | #6 |
| levocabastine effective | #6 |
| severe vernal | #6 |
| rate tbut | #6 |
| tears acinar | #6 |
| ecp markers | #6 |
| regulation benzamidines | #6 |
| tranilast inhibition | #6 |
| upper tarsal conjunctiva | #6 |
| fva landolt | #6 |
| remodeling vkc | #6 |
| instability conjunctival | #6 |
| dressings female | #6 |
| papillae mucous | #6 |
| atopic eyelids | #6 |
| allergic conjunctivitis cac | #6 |
| elasticity cutometer | #6 |
| edema severity | #6 |
| tacrolimus chronic | #6 |
| betamethasone oral | #6 |
| rtpcr epithelial cells | #6 |
| 20 pbs | #6 |
| inflammatory cell densities | #6 |
| tear ecp | #6 |
| tear meniscus patients | #6 |
| topical cys treatment | #6 |
| corneal damage | #6 |
| symptoms vkc | #6 |
| severe ocular inflammation | #6 |
| pcr muc5ac | #6 |
| bengal vital stainings | #6 |
| eosinophils crth2 | #6 |
| topical cys | #6 |
| treatment tacrolimus | #6 |
| ocular surface findings | #6 |
| defect penetrating | #6 |
| cys ocular | #6 |
| strip meniscometry scores | #6 |
| itching conjunctival | #6 |
| findings dry eye | #6 |
| tear stability values | #6 |
| pathogenesis ocular | #6 |
| rose bengal dyes | #6 |
| agents interferometry | #6 |
| treatment postoperative inflammation | #6 |
| elevation refractory | #6 |
| eye evaluated | #6 |
| eyes atopic | #6 |
| fibroblasts conjunctival | #6 |
| testing tear | #6 |
| tears xerophthalmia | #6 |
| cgvhd improvements | #6 |
| steroidal benzophenones | #7 |
| vkc gpc | #7 |
| 4 tear | #7 |
| hrtii rcm | #7 |
| cases preventing | #7 |
| conjunctival brush | #7 |
| meniscometry testing | #7 |
| allergic eyelid | #7 |
| conjunctivitis risk | #7 |
| tears th2 | #7 |
| mmc observed | #7 |
| administration fluorescein | #7 |
| tacrolimustreated eyes | #7 |
| tears alpha | #7 |
| injection oedema | #7 |
| necrotizing anterior | #7 |
| prostaglandin atopic | #7 |
| conclusion mmc | #7 |
| surgery cooling | #7 |
| conjunctivitis dry | #7 |
| increases proliferative | #7 |
| pathogenesis subsequent | #7 |
| ocular inflammatory disorder | #7 |
| ulcers revealed | #7 |
| tear supply | #7 |
| nonparametric tears | #7 |
| nerves tear | #7 |
| inhibitor ono2235 | #7 |
| examination tear | #7 |
| rose bengal fluorescein | #7 |
| tmh measurements | #7 |
| improvements symptom scores | #7 |
| allergic dna | #7 |
| evaluation eyelid | #7 |
| crth2 normal | #7 |
| eczema frequently | #7 |
| pgd2 dependent | #7 |
| key prostaglandin | #7 |
| revealed eosinophils | #7 |
| western blotting nfκb | #7 |
| normal blinking | #7 |
| collected brush | #7 |
| age 325 years | #7 |
| suspension 01 | #7 |
| eyelid surface | #7 |
| mucins periodic | #7 |
| sensation symptom | #7 |
| thought pathogenesis | #7 |
| sources chemokines | #7 |
| corneal lesion | #7 |
| amniotic membrane patching | #7 |
| mucins tears | #7 |
| conjunctival complications | #7 |
| solution bf | #7 |
| eyes ophthalmologists | #7 |
| ulcer corneal | #7 |
| pge2 cox2 levels | #7 |
| sensitization asian | #7 |
| superiority placebo | #7 |
| adult blepharitis | #7 |
| 10 clinical signs | #7 |
| chemotaxis eosinophils | #7 |
| attendance allergic | #7 |
| mmc 005 | #7 |
| accommodating intraocular lens | #7 |
| tacrolimus topical steroids | #7 |
| incidence meibomian | #7 |
| neutrophils corneal | #7 |
| conjunctival inflammatory | #7 |
| conjunctiva brush | #7 |
| silicone plugs | #7 |
| concentrations conjunctival | #7 |
| severe persistent cases | #7 |
| status atopic | #7 |
| procedures radioimmunoassay | #7 |
| gpc vkc | #7 |
| hyperemia adverse | #7 |
| 0001 impression | #7 |
| alpha tears | #7 |
| cytology differ | #7 |
| ulceration healthy | #7 |
| papillae formation | #7 |
| development allergic conjunctivitis | #7 |
| patients comfort level | #7 |
| microscopy conjunctival | #8 |
| scores teros | #8 |
| infrared radiation thermometry | #8 |
| occlusion lacrimal | #8 |
| alterations cornea | #8 |
| conjunctival sensation | #8 |
| techniques keratoconjunctivitis | #8 |
| trabeculectomy amniotic | #8 |
| akc subjects | #8 |
| noninfectious corneal | #8 |
| patients vkc | #8 |
| brush cytology | #8 |
| pathogenesis test | #8 |
| surface teros | #8 |
| tnfalpha eosinophils | #8 |
| sac akc | #8 |
| corneal scores | #8 |
| akc patients controls | #8 |
| classified allergic | #8 |
| 4 chemokines | #8 |
| fva measurements | #8 |
| diameter acinar | #8 |
| values slit | #8 |
| definite dry eye | #8 |
| stainings schirmer | #8 |
| graticule scale | #8 |
| ihc hel | #8 |
| ulcers detected | #8 |
| asia cats | #8 |
| palpebral bulbar | #8 |
| transient burning sensation | #8 |
| blinking body | #8 |
| il4 enzyme | #8 |
| alterations allergic | #8 |
| blink patients | #8 |
| hoc analysis study | #8 |
| ccl5 conjunctiva | #8 |
| blinking desiccation | #8 |
| conjunctivitis eyes | #8 |
| staining hel | #8 |
| rollable intraocular | #8 |
| induced intraocular | #8 |
| controls brush | #8 |
| corneal epithelial lesions | #8 |
| itching hyperemia | #8 |
| eye redness | #8 |
| meniscometry tear | #8 |
| corneal fibroblasts tnfalpha | #8 |
| controls seldi | #8 |
| oedema scores | #8 |
| superficial cells groups | #8 |
| fluorescein rose bengal | #8 |
| 006 degree | #8 |
| age 170 ± | #8 |
| stained hel | #8 |
| mitomycin post | #8 |
| teros | #8 |
| corneal ulcer | #8 |
| betamethasone calcineurin | #8 |
| pollen odds | #8 |
| flare counts | #8 |
| allergic dibenzazepines | #8 |
| radiation thermography | #8 |
| expressions thought | #8 |
| meniscometry scores | #8 |
| patients corneal | #8 |
| conjunctival findings | #8 |
| par2 mast cells | #8 |
| chemotaxis pgd2 | #8 |
| limbalbased conjunctival flap | #8 |
| keratocytes cytokines | #8 |
| underwent tear | #8 |
| teros values | #8 |
| correlation vital | #8 |
| conjunctival fibroblast | #9 |
| blood level tacrolimus | #9 |
| specular microscopic evaluation | #9 |
| operatedon eye | #9 |
| sufficient examination | #9 |
| pathogen allergic | #9 |
| fluorescein rose | #9 |
| tears thermography | #9 |
| clinical ocular findings | #9 |
| pilocarpine tablets | #9 |
| elisa tears | #9 |
| tear level | #9 |
| smart eye | #9 |
| hel 4 | #9 |
| cobblestone papillae | #9 |
| eye normal subjects | #9 |
| differ allergic | #9 |
| diagnosis conjunctivitis | #9 |
| prospective study tacrolimus | #9 |
| supply superior | #9 |
| measurements vital | #9 |
| mmc recurrence | #9 |
| foreign body sensation | #9 |
| hyperemia iop | #9 |
| inflammation steroidal | #9 |
| tacrolimus 95 | #9 |
| pretreatment docosahexaenoic | #9 |
| crth2 expression eosinophils | #9 |
| sensitivity conjunctival | #9 |
| tnfalpha fibroblasts | #9 |
| eye grade | #9 |
| tacrolimus treating | #9 |
| excision intraoperative | #9 |
| vital staining scores | #9 |
| received preserved | #9 |
| untreated asian | #9 |
| observed obstructive | #9 |
| superior limbic | #9 |
| prevalence weather | #9 |
| sio2 pbs | #9 |
| reductase cataract | #9 |
| ono2235 | #9 |
| prevalence vkc | #9 |
| severity corneal | #9 |
| implantation 1cu | #9 |
| wash solution | #9 |
| cases conjunctivitis | #9 |
| level pollutants | #9 |
| symptoms allergic conjunctivitis | #9 |
| histocytological study | #9 |
| diseases conjunctivitis | #9 |
| concentration tears | #9 |
| acid goblet | #9 |
| glaucoma younger age | #9 |
| injection edema | #9 |
| sensitivity confocal | #9 |
| conjunctivitis cases | #9 |
| vital stainings | #9 |
| cys eye | #9 |
| fatigue dry | #9 |
| patients tacrolimus treatment | #9 |
| shield ulcers | #9 |
| stress staining | #9 |
| 0001 schirmer | #9 |
| pollution conjunctivitis | #9 |
| subjective ocular | #9 |
| design eyelid | #9 |
| genes cxc | #9 |
| complain | #10 |
| conjunctivitis japan | #10 |
| shield ulcer | #10 |
| assessed conjunctival | #10 |
| allergic ocular | #10 |
| measuring tear | #10 |
| staining brush | #10 |
| treatment vkc | #10 |
| patients ulcers | #10 |
| functions dry | #10 |
| chemokines cxc chemokines | #10 |
| produced conjunctival | #10 |
| eye surface | #10 |
| insufficient local | #10 |
| evaluation atopic | #10 |
| allergic conjunctivitis spring | #10 |
| humans conjunctival | #10 |
| underwent slit | #10 |
| bengal stainings | #10 |
| central graft | #10 |
| levels tears | #10 |
| compared eyes | #10 |
| substance tears | #10 |
| tears 10 | #10 |
| scale tear | #10 |
| subbasal stromal | #10 |
| drugs conjunctival | #10 |
| humans mucin | #10 |
| tear cytology | #10 |
| vmr values | #10 |
| conjunctival edema | #10 |
| par2 mast | #10 |
| staining oral | #10 |
| muc5ac muc16 | #10 |
| eye infrared | #10 |
| measurement strip | #10 |
| leupeptin benzamidine | #10 |
| allergic bronchitis | #10 |
| nonallergic conjunctivitis | #10 |
| incubated il4 | #10 |
| visante optical | #10 |
| lower tmh | #10 |
| crth2 chemotaxis | #10 |
| status conjunctival | #10 |
| cytometry il4 | #10 |
| total tear ige | #10 |
| lacrimal puncta | #10 |
| cornea eosinophils | #10 |
| laminin actins | #10 |
| sensation ocular | #10 |
| resection regrowth | #10 |
| conjunctivitis atopic | #10 |
| proliferation conjunctival | #10 |
| conjunctivitis histamine | #10 |
| iop hyperemia | #10 |
| eye clinically | #10 |
| conjunctivitis spring | #10 |
| aged conjunctivitis | #10 |
| layer alterations | #10 |
| icam1 tnfalpha | #10 |
| meibomian gland obstruction | #10 |
| improvement tear | #10 |
| topical cyclosporine patients | #10 |
| diagnosis dry eye | #10 |
| ophthalmic adolescent | #10 |
| punctal occlusion | #10 |
| muc16 muc5ac | #10 |
| methods conjunctival | #11 |
| genes corneal | #11 |
| surgery 13 eyes | #11 |
| interleukin4 male | #11 |
| cytometry oligonucleotide | #11 |
| ophthalmic solution | #11 |
| vkc normal | #11 |
| matched dry | #11 |
| common conjunctival | #11 |
| levocabastine hydrochloride | #11 |
| drop artificial | #11 |
| amniotic membrane patch | #11 |
| vmr fva | #11 |
| sensation tear | #11 |
| count conjunctivitis | #11 |
| landolt visual | #11 |
| association outpatient | #11 |
| schirmer1 test | #11 |
| keratitis observed | #11 |
| smart eye camera | #11 |
| patient atopic | #11 |
| initiation tacrolimus | #11 |
| antivcaigg | #11 |
| coherence dry | #11 |
| elicited statistically | #11 |
| elasticity treatment | #11 |
| vkc adolescent | #11 |
| prevalence dry eye | #11 |
| sensation staining | #11 |
| hel hne | #11 |
| palpebral bulbar conjunctiva | #11 |
| elisa il4 | #11 |
| 1 month reduction | #11 |
| purpose metaplasia | #11 |
| diagnosis allergic | #11 |
| disease edition | #11 |
| anesthesia strabismus | #11 |
| vcam1 tnfalpha | #11 |
| cooling operation | #11 |
| weeks papillary | #11 |
| vkc | #11 |
| function ocular | #11 |
| therapy conjunctivitis | #11 |
| fibroblasts pathogenesis | #11 |
| vernal | #11 |
| higher muc1 | #11 |
| test tear | #11 |
| lamp microscope | #11 |
| tears conjunctival | #11 |
| preserved artificial | #11 |
| eosinophils prostaglandin | #11 |
| supratarsal injection | #12 |
| eye diagnosed | #12 |
| receptor crth2 | #12 |
| lacrimal punctal | #12 |
| corneal shield | #12 |
| leupeptins mast | #12 |
| extracts pollens | #12 |
| severe binocular | #12 |
| conventional slit | #12 |
| 001 specimens | #12 |
| specimens eyes | #12 |
| microscopy efficient | #12 |
| surface diabetic | #12 |
| dermatitis tacrolimus | #12 |
| corneal aesthesiometry | #12 |
| projects tears | #12 |
| controls antibody titers | #12 |
| keratoconjunctivitis patients | #12 |
| mgd controls | #12 |
| density muc5ac | #12 |
| fluorescein scores | #12 |
| mmhg elevation | #12 |
| 1821 subjects | #12 |
| highspeed highresolution | #12 |
| patients sac | #12 |
| biomarker allergic | #12 |
| ccl11 conjunctiva | #12 |
| conjunctival injection | #12 |
| 002 ophthalmic | #12 |
| drugs pge2 | #12 |
| cornea density | #12 |
| 1cu iol | #12 |
| expression 8 genes | #12 |
| pemirolast potassium | #12 |
| fva visual | #12 |
| findings conjunctival | #12 |
| fva vmr | #12 |
| density acinar | #12 |
| 1cu accommodating | #12 |
| immunologic rejection | #12 |
| tears conjunctivitis | #12 |
| acids chemokine | #12 |
| radiography tears | #12 |
| iop younger | #12 |
| iop glucocorticoids humans | #12 |
| coated lactoferrin | #12 |
| levocabastine patients | #12 |
| ulcers squamous | #12 |
| keratoplasty glaucoma | #12 |
| damage height | #12 |
| selected severity | #12 |
| appearance atopic | #12 |
| anterior segment photography | #13 |
| tear functions | #13 |
| time fluorescein | #13 |
| glaucoma younger | #13 |
| tear hel | #13 |
| specimens levels | #13 |
| dry eye examination | #13 |
| syndrome reactivation | #13 |
| coherence viscosupplements | #13 |
| schirmers test values | #13 |
| papillary samples | #13 |
| temperature cataract | #13 |
| suspensions tacrolimus | #13 |
| scraped samples | #13 |
| symptoms conjunctival | #13 |
| 5ac ophthalmic | #13 |
| glaucoma keratoplasty | #13 |
| months healed | #13 |
| chemokines stimulation | #13 |
| conjunctival oedema | #13 |
| treatment allergic conjunctivitis | #13 |
| japan keratoconjunctivitis | #13 |
| inflammation tear | #13 |
| keratocytes incubated | #13 |
| cell flare | #13 |
| sd105 | #13 |
| objective signs | #13 |
| upper tarsal | #13 |
| improvement vital | #13 |
| week corneal | #13 |
| called giant | #13 |
| interferometry tear | #13 |
| corneal complications | #13 |
| compared postsurgical | #13 |
| protein conjunctival | #13 |
| bengal fluorescein | #13 |
| ulcers corneal | #13 |
| vmr measurements | #13 |
| stability vital | #13 |
| outcomes 01 | #13 |
| blood levels tacrolimus | #13 |
| fluorometholone fml | #13 |
| thirty eyes | #13 |
| applied operation | #13 |
| conclusions ocular | #13 |
| remodeling relevant | #13 |
| aged disposable | #13 |
| topical cyclosporine treatment | #13 |
| epithelial disease | #13 |
| schirmer1 | #14 |
| functions corneal | #14 |
| test rose | #14 |
| occlusion dry | #14 |
| blinking patients | #14 |
| pilocarpine effective | #14 |
| dry eye controls | #14 |
| visits allergic | #14 |
| secrete mediators | #14 |
| fibroblast damage | #14 |
| higher allergic | #14 |
| density tear | #14 |
| solutions retrospective | #14 |
| factors conjunctivitis | #14 |
| flare count | #14 |
| radioimmunoassay tears | #14 |
| cornea endophthalmitis | #14 |
| conjunctivitis vernal | #14 |
| epithelial muc5ac | #14 |
| bf 01 | #14 |
| conjunctivitis background | #14 |
| clinical corneal | #14 |
| benzamidines blotting | #14 |
| conjunctival allergen challenge | #14 |
| clinically allergic | #14 |
| proliferative lesion | #14 |
| fluorometholone humans | #14 |
| vehicle eye | #14 |
| mcfg treatment | #14 |
| eyes 002 | #14 |
| fungi adolescent | #14 |
| conjunctival muc5ac | #14 |
| conjunctival impression | #14 |
| 14 flare | #14 |
| rtpcr cytometry | #15 |
| adherence fibroblasts | #15 |
| complications height | #15 |
| receptor pgd2 | #15 |
| bilateral conjunctivitis | #15 |
| diseases 2020 | #15 |
| olopatadine 01 | #15 |
| investigated corneal | #15 |
| day bf | #15 |
| irritation scores | #15 |
| topical 01 | #15 |
| ocular acrylic | #15 |
| firstline drug | #15 |
| eye drop treatment | #15 |
| monitoring tear | #15 |
| superior conjunctiva | #15 |
| agents blepharitis | #15 |
| blepharitis conjunctivitis | #15 |
| patients vernal | #15 |
| damaged fibroblasts | #15 |
| ocular surface mucins | #15 |
| correlation tear | #15 |
| improvement corneal | #15 |
| complications mmc | #15 |
| corneal recurrence | #15 |
| ulcer echinocandins | #15 |
| mucous discharge | #15 |
| effects benzalkonium | #15 |
| ige ecp | #15 |
| examined existence | #15 |
| evaluation conjunctival | #15 |
| basal tear secretion | #15 |
| steroidal cornea | #15 |
| tranilast anti | #15 |
| analysis par2 | #15 |
| occlusion rose | #15 |
| vkc methods | #15 |
| ocular itching | #15 |
| giant papillary | #15 |
| occlusion oct | #15 |
| tmh values | #15 |
| bromobenzenes child | #15 |
| mmc female follow | #15 |
| improvement subjective symptoms | #15 |
| expression realtime pcr | #15 |
| ophthalmology tokyo | #15 |
| surface vital | #15 |
| cytology brush | #15 |
| objective ocular | #16 |
| female goblet | #16 |
| temperature conjunctiva | #16 |
| controls papillary | #16 |
| reduction goblet | #16 |
| eosinophils receptor | #16 |
| segment photography | #16 |
| treatment eyelid | #16 |
| ulcers positive | #16 |
| assessment conjunctival | #16 |
| lacrimation | #16 |
| odds ratio remission | #16 |
| hours visit | #16 |
| measurements tear | #16 |
| alpha ortho | #16 |
| ari administration | #16 |
| total clinical scores | #16 |
| safety 01 | #16 |
| ige correlation | #16 |
| 2 conjunctival | #16 |
| fungi odds | #16 |
| dust allergic | #16 |
| patients vernal keratoconjunctivitis | #16 |
| signs ded | #17 |
| warmer treatment | #17 |
| wear soft | #17 |
| staining muc1 | #17 |
| ceramide gel | #17 |
| fibroblasts mcp1 | #17 |
| inhibitor ari | #17 |
| 13 females age | #17 |
| expression eotaxin1 | #17 |
| eyes schirmer | #17 |
| initiation objective | #17 |
| meniscometry | #17 |
| evaluation inflammatory | #17 |
| betamethasone induced | #17 |
| corneal sensation | #17 |
| age dry | #17 |
| strip meniscometry | #17 |
| agents cedrus | #17 |
| ocular allergic inflammation | #17 |
| drops eyes | #17 |
| muc16 mrna | #17 |
| conjunctival samples | #17 |
| fibroblasts damaged | #17 |
| increased goblet cells | #17 |
| sclera trabeculectomy | #17 |
| clearance corneal | #17 |
| analyzed 005 | #17 |
| 20 normal patients | #17 |
| inflammation blotting | #17 |
| cytology corneal | #18 |
| conclusion ocular | #18 |
| technique glaucoma | #18 |
| male ophthalmic solutions | #18 |
| rantes response | #18 |
| ocular surface status | #18 |
| evaluation tear | #18 |
| types dry eye | #18 |
| inflammation lenses | #18 |
| cytology decrease | #18 |
| trabeculectomy glaucoma | #18 |
| studies rose | #18 |
| induce corneal | #18 |
| noncl wearers | #18 |
| differentiation inflammatory cells | #18 |
| decrease ocular | #18 |
| lower eyes | #18 |
| higher tears | #18 |
| tear evaporation rate | #18 |
| correlation clinical signs | #18 |
| dibenzazepines dibenzoxepins | #18 |
| intraoperative 002 | #18 |
| tear function | #18 |
| fibroblasts giant | #18 |
| concentrations corneal | #18 |
| obstructive dysfunction | #18 |
| ulceration subjects | #18 |
| ulcers compared | #18 |
| tnfα inflammatory response | #18 |
| associations level | #18 |
| bengal sjogren | #18 |
| 30 ige | #18 |
| complete staining | #18 |
| pollen fungi | #18 |
| cd45 inflammatory | #18 |
| groups spt | #18 |
| test tears | #18 |
| aged cautery | #19 |
| human conjunctival | #19 |
| conjunctivitis topical | #19 |
| sma performed | #19 |
| measurements visante | #19 |
| aged ophthalmic | #19 |
| microscopy scans | #19 |
| steroid female | #19 |
| 1151 years | #19 |
| seldi proteinchip | #19 |
| total signs | #19 |
| inflammatory cells patients | #19 |
| vernal keratoconjunctivitis | #19 |
| outpatient attendance | #19 |
| beta1 il1beta | #19 |
| seldi analysis | #19 |
| staining scores | #19 |
| prospective study eyes | #19 |
| early efficacy | #19 |
| mitomycin ophthalmologic | #19 |
| sodium 01 | #19 |
| dha pretreatment | #19 |
| operation applied | #19 |
| evaluated infrared | #19 |
| 3 severe | #19 |
| ige tear | #19 |
| limbal allograft | #19 |
| effective tacrolimus | #19 |
| periostin biomarker | #19 |
| temperature artificial | #19 |
| subjects underwent | #19 |
| eosinophils adhered | #19 |
| explain pathogenesis | #20 |
| xerophthalmia adolescent | #20 |
| height tmh | #20 |
| evaluate noninferiority | #20 |
| surface findings | #20 |
| tears corneal | #20 |
| lower dry | #20 |
| plaques graded | #20 |
| patients strip | #20 |
| decreased conjunctival | #20 |
| summarized based | #20 |
| bilateral agerelated cataract | #20 |
| 022 pg | #20 |
| treated 01 | #20 |
| allergic female humans | #20 |
| proteins tears | #20 |
| conjunctivitis primary | #20 |
| pollen association | #20 |
| corneal impression | #20 |
| common ocular disorders | #20 |
| ulcers cell | #20 |
| mucin alterations | #20 |
| echinocandins eye | #20 |
| conjunctivitis caused | #20 |
| symptoms allergic | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| conclusion tacrolimus | #20 |
| improvements ocular | #20 |
| persistent epithelial defect | #20 |
| cytology upper | #20 |
| cornea clinical | #21 |
| eye control | #21 |
| symptoms include | #21 |
| adhesion fibroblast | #21 |
| ige groups | #21 |
| acuity assessment | #21 |
| tears blood | #21 |
| microscopy patients | #21 |
| preventing corneal | #21 |
| eosinophils flow cytometry | #21 |
| patients concomitant treatment | #21 |
| reduction topical | #21 |
| crth2 expressed | #21 |
| radiation thermometer | #21 |
| cultured conjunctiva | #21 |
| keratoconjunctivitis atopic | #21 |
| ocular symptoms signs | #21 |
| peripheral blood eosinophils | #21 |
| lipid oxidative | #21 |
| reaction tears | #21 |
| conclusions topical | #21 |
| surface mucin | #21 |
| induced topical | #21 |
| methane nonmethane hydrocarbons | #21 |
| levels hel | #21 |
| eye smaller | #21 |
| fluorescence postoperative | #21 |
| patients cedar | #21 |
| conjunctiva role | #21 |
| film lipid | #21 |
| 005 topical | #22 |
| correlation humidity | #22 |
| therapies allergic | #22 |
| fibroblasts anti | #22 |
| eyes nerve | #22 |
| types ocular | #22 |
| haze photorefractive | #22 |
| flare anterior | #22 |
| serum periostin patients | #22 |
| fluorescein staining | #22 |
| negative lower | #22 |
| accommodation amplitude | #22 |
| 01 tacrolimus | #22 |
| mgd adult | #22 |
| epithelial lipid | #22 |
| muc5ac patients | #22 |
| palpebral conjunctiva | #23 |
| preschool conjunctivitis | #23 |
| 215 ± | #23 |
| pge2 supernatants | #23 |
| lamp examinations | #23 |
| solution compared | #23 |
| patients topical steroids | #23 |
| diseases diclofenac | #23 |
| tests adenovirus | #23 |
| cooling applied | #23 |
| corneal fluorescein | #23 |
| disease atopic | #23 |
| hrt confocal | #23 |
| il4 tnf | #23 |
| tear dynamics | #23 |
| layer interferometry | #23 |
| score deqs | #23 |
| subjects squamous | #23 |
| labeling tears | #23 |
| solution corneal | #23 |
| 5 females | #23 |
| prospectively surgery | #23 |
| 01 severe | #23 |
| function mucin | #23 |
| blood concentration tacrolimus | #23 |
| warming device | #24 |
| interleukin4 oligonucleotide | #24 |
| ocular allergies | #24 |
| tarsal conjunctiva | #24 |
| formation allergic | #24 |
| edema drug | #24 |
| control tear | #24 |
| 27yearold male patient | #24 |
| fungal corneal | #24 |
| samples conjunctival | #24 |
| tokyo dental | #24 |
| patients tacrolimus ointment | #24 |
| layer tear | #24 |
| signs serum | #24 |
| diseases web | #24 |
| bengal tears | #24 |
| conjunctiva diabetes | #24 |
| vkc patients | #24 |
| vital staining | #24 |
| cell meter | #24 |
| surface tear | #24 |
| histamine development | #24 |
| local allergic reaction | #24 |
| dermatitis improved | #24 |
| antigen conjunctiva | #25 |
| confocal prospective | #25 |
| vkc compared | #25 |
| rtpcr rsv | #25 |
| steroid eye | #25 |
| eyes epithelial | #25 |
| level tears | #25 |
| corneal plaques | #25 |
| rsv rtpcr | #25 |
| slitlamp examinations | #25 |
| atopic eosinophils humans | #25 |
| 0001 dry | #25 |
| staining goblet | #25 |
| density squamous | #25 |
| superficial cells | #25 |
| patients atopic diseases | #25 |
| dynamics tear | #25 |
| bengal scores | #25 |
| protein rtpcr | #25 |
| vcam1 activated | #25 |
| schedule eosinophil | #25 |
| solutions corneal | #26 |
| damage adhesion | #26 |
| aureus detected | #26 |
| subjects measuring | #26 |
| diseases ambient | #26 |
| 100 nylon | #26 |
| conjunctival inflammation | #26 |
| level il4 | #26 |
| rapid epithelialization | #26 |
| eyes topical | #26 |
| correlated corneal | #26 |
| 005 immunoreactive | #26 |
| human α defensin | #26 |
| lnfs | #26 |
| specific ige positivity | #26 |
| statistical decrease | #26 |
| treatment meibomian | #26 |
| actins collagen | #26 |
| corneal ulcers | #26 |
| postkeratoplasty glaucoma | #26 |
| symptoms itching | #26 |
| acinar unit | #26 |
| singletreatment groups | #26 |
| tbut tear | #26 |
| smallincision cataract surgery | #26 |
| keratoconjunctivitis caused | #26 |
| adhered fibroblasts | #26 |
| conjunctivitis | #26 |
| conclusions improvement | #26 |
| slit lamp examinations | #26 |
| wheal diameter | #26 |
| dmem f12 medium | #26 |
| 01 topical | #26 |
| alpha eosinophils | #27 |
| oct prospective | #27 |
| 01 cyclosporine | #27 |
| associations prevalence | #27 |
| conjunctival epithelial | #27 |
| antibodies brush | #27 |
| child cytological | #27 |
| lymphocytes specimens | #27 |
| cytometry chemotaxis | #27 |
| interleukin4 polymerase | #27 |
| tear ocular | #27 |
| epinastine | #27 |
| prescribed topical | #27 |
| therapy conjunctiva | #27 |
| 005 symptoms | #27 |
| density subbasal | #27 |
| eosinophils fibroblasts | #27 |
| reaction sensation | #27 |
| factor exacerbation | #27 |
| conjunctiva dexamethasone | #28 |
| provide relief | #28 |
| diseases proliferative | #28 |
| prevalence allergic diseases | #28 |
| 2 iol | #28 |
| 4 5ac | #28 |
| eosinophil adherence | #28 |
| severe ocular | #28 |
| giant papillae | #28 |
| il13 il1beta | #28 |
| assessment tear | #28 |
| corneal vivo | #28 |
| solutions ophthalmologic | #28 |
| stress atopic | #28 |
| chemotactic activity eosinophils | #28 |
| conjunctival epithelial cells | #28 |
| assay eosinophils | #28 |
| papillae patients | #28 |
| objective scores | #28 |
| underwent immunohistochemical | #28 |
| ophthalmic | #28 |
| corneal ulceration | #28 |
| cys treatment | #29 |
| aged thermography | #29 |
| inhibited tranilast | #29 |
| performed morphometric | #29 |
| eye mask | #29 |
| conjunctiva dose | #29 |
| corneal conjunctival | #29 |
| scores schirmer | #29 |
| allergic regulation | #29 |
| rosebengal | #29 |
| ketotifen fumarate | #29 |
| sac compared | #29 |
| 5ac mucins | #29 |
| disease periostin | #29 |
| flare cell | #29 |
| studies conjunctivitis | #29 |
| thermography adolescent | #29 |
| numbers inflammatory | #29 |
| redness eye | #30 |
| effective artificial | #30 |
| conjunctivitis humans | #30 |
| conjunctivitis patients | #30 |
| inhibitors pollen | #30 |
| mucins ophthalmic | #30 |
| infection conjunctival | #30 |
| tear ige | #30 |
| expressed crth2 | #30 |
| regrowth observed | #30 |
| common adverse reaction | #30 |
| symptoms accompanying | #30 |
| eye common | #30 |
| minutes visit | #30 |
| syndromes equipment | #30 |
| palpebral | #30 |
| tear serum | #30 |
| specificity tears | #30 |
| ocular surface alterations | #30 |
| dermatitis efficacy | #30 |
| fibroblasts protease | #30 |
| il2r serum | #30 |
| atopic diagnostic | #30 |
| conjunctiva cells | #30 |
| recruitment day | #30 |
| properties tears | #31 |
| fibroblasts pcr | #31 |
| neutrophils severity | #31 |
| epithelial mucins | #31 |
| schirmer scores | #31 |
| meibomian gland secretion | #31 |
| scores corneal | #31 |
| expressed eosinophils | #31 |
| vegf cultured | #31 |
| combinations eosinophils | #31 |
| ige negative | #31 |
| inflammation atopic | #31 |
| pathogenesis corneal | #31 |
| disease summarized | #31 |
| dermatitis purpose | #31 |
| acuity fva | #31 |
| worse observed | #31 |
| hel levels | #31 |
| levels july | #31 |
| atopic 10 | #31 |
| analysis tears | #32 |
| eye sjögren | #32 |
| signs improved | #32 |
| reduced steroid | #32 |
| keratoconjunctivitis | #32 |
| substantial interrater agreement | #32 |
| diagnosed dry | #32 |
| deqs | #32 |
| tear meniscus height | #32 |
| prostaglandin cell | #32 |
| tgfbeta1 il1beta | #32 |
| conjunctival cells | #32 |
| western blotting effects | #32 |
| limbus cornea | #32 |
| sign scores | #32 |
| schirmer test values | #32 |
| expressibility | #32 |
| edema correlated | #33 |
| 4 grades | #33 |
| levocabastine | #33 |
| count prostaglandin | #33 |
| immunoglobulin interferometry | #33 |
| visante | #33 |
| muc 1 | #33 |
| ige histamine | #33 |
| allergic double | #33 |
| iop induced | #33 |
| numbers quantitative | #33 |
| seasonal young | #33 |
| haze score | #33 |
| signs evaluated | #33 |
| conclusions confocal | #33 |
| atopic skin disease | #33 |
| film break | #33 |
| conjunctiva cytokines | #34 |
| proteinchip array | #34 |
| fluorometholone glucocorticoids | #34 |
| eye 10 | #34 |
| 01 effective | #34 |
| il1beta tgfbeta1 | #34 |
| intraocular pressure surgery | #34 |
| clinical signs patients | #34 |
| bengal staining | #34 |
| 10 objective | #34 |
| therapy histamine | #34 |
| treatment mgd | #34 |
| alpha fibroblasts | #34 |
| fibroblasts purpose | #34 |
| eyes corneal | #34 |
| adult asthenopia | #35 |
| interrater reproducibility | #35 |
| eye 20 | #35 |
| 6 months conclusion | #35 |
| hypertension tacrolimus | #35 |
| cyclosporine cys | #35 |
| virus capsid antigen | #35 |
| mucins prospective | #35 |
| objective symptoms | #35 |
| tear stability | #35 |
| schirmer 1 | #36 |
| tear samples | #36 |
| tear clearance | #36 |
| efficacy groups | #36 |
| humans keratoconjunctivitis | #36 |
| resection 005 | #36 |
| anterior scleritis | #36 |
| vdt users | #36 |
| differential dry | #36 |
| measured tear | #36 |
| severe allergic | #36 |
| diseases eosinophil | #36 |
| functional visual acuity | #36 |
| ocular surface inflammation | #36 |
| eyes acrysof | #36 |
| recurrence corneal | #37 |
| wellrecognized risk | #37 |
| induced iop | #37 |
| conducted compliance | #37 |
| schirmer 1 test | #37 |
| scleritis episcleritis | #37 |
| 002 mmc | #37 |
| oct effective | #37 |
| contact lens surface | #37 |
| tacrolimus 12 | #37 |
| tenon anesthesia | #37 |
| tears tumor | #37 |
| laser flarecell meter | #37 |
| delefilcon | #37 |
| eyelid skin | #37 |
| device eye | #38 |
| exhibited correlation | #38 |
| aged olopatadine | #38 |
| phacoemulsification implantation | #38 |
| pemirolast | #38 |
| allergic cromolyn | #38 |
| 002 mitomycin | #38 |
| gland lipid | #38 |
| post cataract | #38 |
| cac japanese | #38 |
| 0001 specimens | #39 |
| cells conjunctiva | #39 |
| infiltration corneal | #39 |
| conjunctiva limbus | #39 |
| accommodating intraocular | #39 |
| solutions patient | #39 |
| cyclosporine dry | #39 |
| response pretreatment | #39 |
| atopic dry | #39 |
| degree 20 | #39 |
| tests diagnostic accuracy | #39 |
| 005 oct | #39 |
| tears eye | #39 |
| patients dry eye | #39 |
| eye patients | #40 |
| endothelial rejection | #40 |
| biomarkers conjunctiva | #40 |
| ulcers control | #40 |
| tmh | #40 |
| pharmacology clinical efficacy | #40 |
| samples eyes | #40 |
| drops corneal | #40 |
| acid chemokine | #40 |
| subjects specimens | #40 |
| decreased inflammation | #40 |
| epitheliopathy | #41 |
| stimulate vascular | #41 |
| ecp concentrations | #41 |
| pollution severe | #41 |
| treatment dry | #41 |
| conjunctivitis gpc | #41 |
| il1beta vegf | #41 |
| homologous visual | #41 |
| treated topical | #41 |
| vegf il1beta | #41 |
| eyes superior | #41 |
| α pge2 | #41 |
| october july | #42 |
| scans underwent | #42 |
| allergens conjunctivitis | #42 |
| corneal epithelia | #42 |
| day eye | #42 |
| efficient noninvasive | #42 |
| break time | #42 |
| eyelid edema | #43 |
| diseases 2017 | #43 |
| hydrocarbons data | #43 |
| microscopy central | #43 |
| instability decreased | #43 |
| rollable | #43 |
| cytology revealed | #43 |
| conjunctival hyperemia | #43 |
| keratolimbal | #43 |
| limbus corneal | #43 |
| meniscus treatment | #43 |
| surface years | #43 |
| revised 2010 | #43 |
| eye 0001 | #44 |
| elasticity patients | #44 |
| epithelial defect | #44 |
| tryptase par2 | #44 |
| collagens fibronectin | #44 |
| il1beta il4 | #44 |
| abovementioned drugs | #44 |
| oct assessment | #44 |
| tear meniscus | #44 |
| subjective symptom | #44 |
| patients rhinoconjunctivitis | #44 |
| agents keratoconjunctivitis | #44 |
| cautery female | #44 |
| activated il4 | #44 |
| tacrolimus treatment | #44 |
| fibroblasts eosinophils | #45 |
| users contact | #45 |
| bovine enteric | #45 |
| rose bengal staining | #45 |
| graded 3 | #45 |
| body sensation | #45 |
| adult chemotaxis | #45 |
| micafungin mcfg | #45 |
| laser microscopy | #45 |
| metaplasia mucin | #45 |
| inflammation ocular surface | #45 |
| metaplasia grade | #45 |
| formation corneal | #45 |
| 24 seconds | #45 |
| surgery uncorrected | #45 |
| fibroblasts expression | #45 |
| superficial punctate keratitis | #45 |
| signs score | #45 |
| japan particulate | #45 |
| recruiting chemokines | #45 |
| fourgrade scale | #45 |
| surface inflammation | #45 |
| elevation iop | #45 |
| correlation inflammation | #45 |
| topical tacrolimus treatment | #45 |
| case corneal | #45 |
| understanding ocular | #45 |
| 17 japanese patients | #46 |
| seconds controls | #46 |
| staining inflammatory | #46 |
| status ocular | #46 |
| tryptases regulation | #46 |
| staining conjunctival | #46 |
| suspension effective | #46 |
| graticule | #46 |
| posttreatment findings | #46 |
| conjunctival | #46 |
| efficacy combined therapy | #46 |
| il13 serum | #46 |
| fluorometholone | #46 |
| surface disease | #46 |
| efficacy 01 | #46 |
| corneal cells | #46 |
| rate ocular | #47 |
| allergic female histamine | #47 |
| diameter plant | #47 |
| purpose efficacy | #47 |
| suspension 4 | #47 |
| ulcer score | #47 |
| blood level | #47 |
| positive muc5ac | #47 |
| patients 01 | #47 |
| visante oct | #47 |
| cyclosporine ophthalmic | #48 |
| enhanced benefits | #48 |
| stromal nerve | #48 |
| dexamethasone anti | #48 |
| muc5ac mrna | #48 |
| brush cytology specimens | #48 |
| sac patients | #48 |
| eyes month | #48 |
| implantation acrysof | #48 |
| complications corneal | #48 |
| eyelid warming | #48 |
| stimulation chemokine | #48 |
| 1cu | #49 |
| male tears | #49 |
| eosinophils epithelium | #49 |
| objective findings | #49 |
| expression crth2 | #49 |
| fibroblasts incubated | #49 |
| cxc chemokine genes | #49 |
| adult ca125 | #49 |
| visits air | #49 |
| ocular signs | #49 |
| keratocytes fibroblasts | #49 |
| tacrolimus female | #49 |
| trabeculectomy eyes | #49 |
| concentrations tears | #49 |
| total severity score | #50 |
| dyes fluorophotometry | #50 |
| decreased tear | #50 |
| schirmers test | #50 |
| patient eyes | #50 |
| trabeculectomy mitomycin | #50 |
| test ocular | #50 |
| measuring corneal | #50 |
| aged blinking | #50 |
| inflammation conjunctiva | #50 |
| meniscus height | #50 |
| ulcers purpose | #50 |
| disposable soft | #50 |
| 4 normal controls | #50 |
| effects docosahexaenoic acid | #51 |
| reduction score | #51 |
| ocular surface cells | #51 |
| diagnosis dry | #51 |
| members japan | #51 |
| markers atopic | #51 |
| crth2 expression | #51 |
| scls | #51 |
| lenses scls | #51 |
| cells brush | #51 |
| inflammation cataract | #51 |
| periostin patients | #51 |
| stability corneal | #52 |
| eye normal | #52 |
| biomarker diseases | #52 |
| eyelid margins | #52 |
| inflammation decline | #52 |
| pcr tgf | #52 |
| severity objective | #52 |
| examination parameters | #52 |
| reaction vehicle | #52 |
| tears tomography | #52 |
| atopic groups | #52 |
| month initiation | #52 |
| differential eosinophil | #53 |
| acuity values | #53 |
| bromfenac | #53 |
| stromal nerves | #53 |
| presence rsv | #54 |
| scores tear | #54 |
| obstructive mgd | #54 |
| chloride bak | #54 |
| suspension treatment | #54 |
| oxidation adolescent | #54 |
| limbic keratoconjunctivitis | #54 |
| lacrimal glands | #54 |
| 005 month | #54 |
| vegf protein secretion | #54 |
| atopic enterotoxins | #55 |
| antagonists allergic | #55 |
| combinedtreatment | #55 |
| adult conjunctivitis | #55 |
| conjunctiva drug | #55 |
| local cytokine production | #55 |
| epithelial cells expression | #55 |
| aged pollen | #55 |
| surface clinical | #55 |
| ocular signs symptoms | #55 |
| allergies adolescent | #56 |
| pain photophobia | #56 |
| dysfunction atopic | #56 |
| 3 dry | #56 |
| solution placebo | #56 |
| cornea cyclooxygenase | #56 |
| mucin layer | #56 |
| film ocular | #56 |
| mucin2 mucin4 | #56 |
| atopic patients | #56 |
| topical adolescent | #56 |
| plant pollens | #56 |
| mechanism giant | #56 |
| eosinophil cationic | #56 |
| ded adult | #56 |
| specular microscopic | #56 |
| giant papillary conjunctivitis | #57 |
| humans interleukin4 | #57 |
| insensible administration | #57 |
| accommodating iol | #57 |
| inflammation pge2 | #57 |
| chemotactic responses | #57 |
| penetrating limbus | #57 |
| papilla formation | #58 |
| alpha defensins | #58 |
| seventyeight eyes | #58 |
| staining tear | #58 |
| maximum blood concentration | #58 |
| drop treatment | #58 |
| schiff staining | #58 |
| objective sign | #58 |
| findings criteria | #59 |
| pm25 prevalence | #59 |
| type allergic | #59 |
| intraoperative mitomycin | #59 |
| tear instability | #59 |
| disease eyes | #59 |
| release inhibitor | #60 |
| evaluation items | #60 |
| signs severe | #60 |
| tacrolimus ointment treatment | #60 |
| pcr severe | #60 |
| mmc 2 | #60 |
| daily disposable | #60 |
| diabetic corneal | #60 |
| compared 0001 | #60 |
| syndromes female | #60 |
| punctal | #61 |
| thermography adult | #61 |
| nonsteroidal blotting | #61 |
| correlation patients | #61 |
| allergen mediated | #62 |
| eotaxin1 expression | #62 |
| prostaglandin patients | #62 |
| eyes 16 | #62 |
| values tended | #62 |
| specimens histopathologic | #62 |
| expression eyes | #62 |
| combination epithelium | #62 |
| amplitude accommodation | #62 |
| total clinical | #62 |
| sac age | #63 |
| chamber body | #63 |
| corneal erosion | #63 |
| hypersensitivity japan | #63 |
| oral pilocarpine | #63 |
| ulcer endophthalmitis | #63 |
| conjunctiva patients | #63 |
| patient corneal | #63 |
| corneal stem | #63 |
| micafungin treatment | #63 |
| il4 role | #63 |
| dexamethasone production | #64 |
| eye adolescent | #64 |
| positive mucin | #64 |
| density inflammatory | #64 |
| cornea dry | #64 |
| evaluation corneal | #64 |
| il4 culture | #64 |
| radioimmunoassay respiratory | #64 |
| factor allergic | #64 |
| tears biomarkers | #65 |
| conclusions corneal | #65 |
| dust house | #65 |
| viral radioimmunoassay | #65 |
| live rsv | #65 |
| mucins rna | #65 |
| microscope methods | #65 |
| treatment immunosuppressive agents | #66 |
| layer speed | #66 |
| surface epithelial | #66 |
| diagnosis therapies | #66 |
| cases atopic | #66 |
| period oral | #67 |
| effects 01 | #67 |
| 003 treatment | #67 |
| female fluorophotometry | #67 |
| persistent epithelial | #67 |
| agents keratoplasty | #67 |
| cyclosporine eye | #67 |
| housedust | #68 |
| ointment treatment | #68 |
| time vital | #68 |
| eye dry | #68 |
| patients eosinophils | #69 |
| counter drugs | #69 |
| fibroblasts examined | #69 |
| occlusion 005 | #69 |
| aged tears | #69 |
| glaucoma graft | #69 |
| fibroblasts corneal | #69 |
| ophthalmic solutions | #69 |
| 1436 patients | #70 |
| crth2 receptor | #70 |
| 22 eyes | #70 |
| schirmer test | #70 |
| visit 4 | #70 |
| values rose | #70 |
| crth2 pgd2 | #70 |
| rhinoconjunctivitis allergic | #70 |
| dust 20 | #71 |
| allergic dermatitis | #71 |
| factors tears | #71 |
| drops treatment | #71 |
| lenses dry | #71 |
| tear production | #72 |
| 16 eyes | #72 |
| glaucoma trabeculectomy | #72 |
| ige eosinophil | #72 |
| bulbar conjunctiva | #72 |
| antiallergic agent | #73 |
| extraction conjunctiva | #73 |
| punctate keratopathy | #73 |
| immunosuppressive treatment patients | #73 |
| fluorophotometry humans | #73 |
| pyridines pyrimidinones | #73 |
| pollution prevalence | #73 |
| epithelial structure | #73 |
| surface mucins | #73 |
| fml | #73 |
| liquid conjunctiva | #73 |
| tacrolimus patients | #74 |
| agents intraocular | #74 |
| mcfg | #74 |
| evaluation dry | #74 |
| eosinophils expressed | #74 |
| inflammatory cell numbers | #74 |
| iol acrysof | #74 |
| improved infrared | #75 |
| laser flare | #75 |
| pilocarpine prospective | #75 |
| dust epidemiologic | #75 |
| 1 month baseline | #75 |
| healthy individuals patients | #75 |
| cedar pollen | #75 |
| completely controlled | #75 |
| guidelines allergic | #76 |
| interleukin4 rna | #76 |
| agents interleukin4 | #76 |
| ccchemokine | #76 |
| ophthalmological elasticity | #77 |
| vegf tgfbeta1 | #77 |
| signs treatment | #77 |
| lower tear | #77 |
| cytokines stimulate | #77 |
| capilia | #77 |
| slight elongation | #77 |
| cornea module | #77 |
| studies suspensions | #77 |
| excision recurrence | #77 |
| surgery technique | #77 |
| cytology samples | #77 |
| chemical mediator | #77 |
| concentration il2 | #78 |
| signs observed | #78 |
| severity ocular | #78 |
| drops 1 | #78 |
| japanese guideline | #78 |
| concomitant tacrolimus | #78 |
| pollen compared | #78 |
| allergic environmental | #79 |
| glaucoma penetrating | #79 |
| injection reduction | #79 |
| effects corneal | #79 |
| type allergy | #79 |
| dry eye | #79 |
| extended wear | #79 |
| inhibitors leupeptin | #79 |
| permeability cornea | #79 |
| il4 ige | #79 |
| ocular pain | #79 |
| assay epithelial | #80 |
| mgd patients | #80 |
| mediated par2 | #80 |
| questionnaires tears | #80 |
| medications required | #80 |
| decreased dry | #81 |
| antigens histamine | #81 |
| vegf concentration | #81 |
| prostaglandin reverse | #82 |
| cytology performed | #82 |
| atopic dermatitis study | #82 |
| caused insufficient | #82 |
| patients conjunctivitis | #82 |
| acrysof iol | #82 |
| tear lipid | #83 |
| data tacrolimus | #83 |
| patients staphylococcus aureus | #83 |
| dental college | #83 |
| expression corneal | #83 |
| complications lenses | #83 |
| cytokines vegf | #84 |
| papillae | #84 |
| earlier published data | #84 |
| schirmer | #84 |
| correlation corneal | #84 |
| epithelium ocular | #84 |
| alterations basal | #85 |
| 18 pg | #85 |
| patients dry | #85 |
| inhibitors tryptases | #85 |
| hyperemia induced | #85 |
| human reverse | #85 |
| combined penetrating | #85 |
| temperature patients | #85 |
| 5 grades | #85 |
| scleritis patients | #85 |
| treatment odds ratio | #85 |
| sligkv | #86 |
| edema scores | #86 |
| discharge evaluated | #86 |
| patients eyelid | #86 |
| acuity accommodation | #86 |
| daily outpatient | #86 |
| 284 years | #86 |
| pharmacologic intervention | #86 |
| inflammation eye | #86 |
| tacrolimus young | #87 |
| tacrolimus reduced | #87 |
| confocal ophthalmic | #87 |
| detection limit assay | #87 |
| tears | #88 |
| post keratoplasty | #88 |
| sclera surgical | #88 |
| daily weather conditions | #88 |
| disease conjunctiva | #88 |
| regulation muc5ac | #88 |
| cells keratocytes | #88 |
| assessment dry | #89 |
| seasonal perennial | #89 |
| eyes 30 | #89 |
| findings severe | #89 |
| tryptase inhibitors | #89 |
| tears visual | #89 |
| months signs | #90 |
| lower corneal | #90 |
| temperature cornea | #90 |
| cytocentrifuge preparations | #90 |
| tears adult | #90 |
| glands microscopy | #90 |
| decrease corneal | #90 |
| early ocular | #90 |
| dressings chronic | #90 |
| film breakup | #91 |
| lenses extended | #91 |
| procedures phacoemulsification | #92 |
| eye corneal | #92 |
| laser cell | #92 |
| exposure japan | #92 |
| techniques trabeculectomy | #92 |
| tears administration | #93 |
| 7 visit | #93 |
| conjunctival specimens | #93 |
| stromal corneal | #93 |
| preschool conjunctiva | #93 |
| 005 complications | #93 |
| regulation muc1 | #93 |
| treatment noninfectious | #93 |
| eye cataract surgery | #93 |
| patients correlation | #93 |
| solutions tears | #93 |
| drug fibroblasts | #93 |
| exposure exhaust | #94 |
| case allergic | #94 |
| pollution weather | #94 |
| pgd2 crth2 | #94 |
| classification pathogenesis | #94 |
| reaction physical | #94 |
| induced pgd2 | #95 |
| twentyeight eyes | #95 |
| eosinophils patients | #95 |
| eye higher | #95 |
| studies tears | #95 |
| relevant factor | #95 |
| study cyclosporine | #96 |
| 128 eyes | #96 |
| score objective | #96 |
| protein eosinophilia | #96 |
| staining fluorescein | #96 |
| higher eyes | #96 |
| 4 alterations | #97 |
| treatment ecp | #97 |
| cells hel | #97 |
| production pge2 | #97 |
| 1month treatment | #97 |
| eyes study | #98 |
| eyes positive | #98 |
| vdts | #98 |
| eye tear | #98 |
| staining schirmer | #98 |
| meniscus patients | #98 |
| equivalent 4 | #99 |
| 005 recurrence | #99 |
| surgery 6 months | #99 |
| solution improved | #99 |
| cytology evaluation | #99 |
| management ocular | #99 |
| pseudophakic patients | #99 |
| japan post | #99 |
| terminals contact | #100 |
| local pattern | #100 |
| postoperatively statistically | #100 |
| conjunctiva corneal | #100 |
| ointments tacrolimus | #100 |
| allergic atopic | #100 |
| confocal scanning | #100 |
| corneal abnormalities | #100 |
| cells severity | #100 |
| ulcer patient | #100 |
| eyes 10 | #101 |
| fibroblasts 2 | #101 |
| pathogenesis atopic | #101 |
| severe atopic | #102 |
| disease classified | #102 |
| pathogenesis allergic | #102 |
| effects tranilast | #102 |
| agents conjunctivitis | #102 |
| keratolimbal allograft | #102 |
| therapy conjunctival | #102 |
| subjective comfort | #103 |
| washing solution | #103 |
| prevalence dry | #103 |
| mediated protease | #103 |
| chemotaxis experiments | #103 |
| differences ocular | #104 |
| topical cyclosporine | #104 |
| patients bf | #104 |
| topic premedication | #104 |
| values vital | #104 |
| groups dry | #104 |
| events scores | #104 |
| allergic cytokines | #104 |
| tears young | #104 |
| syndrome epstein | #104 |
| wearing contact | #105 |
| role staphylococcal | #105 |
| inflammation diagnosis | #105 |
| baseline initiation | #105 |
| child conjunctival | #105 |
| aged amnion | #105 |
| conjunctival impression cytology | #105 |
| 14 eyes | #106 |
| parameters ocular | #106 |
| adhesion fibroblasts | #106 |
| pressure keratoplasty | #106 |
| microscopy evaluation | #106 |
| conjunctiva cornea | #106 |
| corneal keratocytes | #107 |
| patients ded | #107 |
| superficial punctate | #107 |
| eotaxin1 | #107 |
| levels radioimmunoassay | #108 |
| dry mouth symptoms | #108 |
| topical tacrolimus | #108 |
| film instability | #108 |
| conjunctiva | #108 |
| induces chemotaxis | #108 |
| scores symptoms | #108 |
| resins aged | #108 |
| lipid layer | #108 |
| acuity acrylic | #108 |
| effects dha | #109 |
| level tacrolimus | #109 |
| 4 dry | #109 |
| il4 human | #109 |
| asian dust | #109 |
| tear evaporation | #109 |
| corneal inflammatory | #109 |
| lacrimal salivary | #110 |
| controls inflammatory | #110 |
| japanese guidelines | #110 |
| conjunctival epithelium | #110 |
| eyes 9 | #110 |
| steroids administration | #110 |
| dysfunction mgd | #110 |
| increased evaporation | #110 |
| topical instillation | #111 |
| severity markers | #111 |
| vcam1 antibody | #112 |
| eye camera | #112 |
| pcr rsv | #113 |
| strabismus surgery | #113 |
| solutions platelet | #113 |
| anterior segment inflammation | #113 |
| papillary conjunctivitis | #113 |
| dibenzoxepins | #113 |
| layer patients | #114 |
| eye irritation | #114 |
| diagnosed allergic | #114 |
| lesions atopic | #114 |
| incision cataract | #114 |
| grading scores | #114 |
| seconds 0001 | #115 |
| male mucin | #115 |
| findings severity | #115 |
| allergic eye | #115 |
| sjögrens syndrome patients | #115 |
| conjunctival cell | #115 |
| 13 eyes | #115 |
| cholinergic treatment | #115 |
| goblet cell density | #115 |
| edition revised | #116 |
| selective histamine | #116 |
| patients seasonal | #117 |
| metaplasia mucins | #117 |
| viscosupplements aged | #117 |
| ophthalmology prevalence | #117 |
| asia dust | #117 |
| cooling increased | #117 |
| samples stained | #117 |
| effects docosahexaenoic | #118 |
| sag genes | #118 |
| generation pge2 | #118 |
| molecule1 interleukin4 | #118 |
| immunologic receptors prostaglandin | #118 |
| revealed higher | #119 |
| acuity distance | #119 |
| chemotaxis induced | #119 |
| iop observed | #119 |
| topical steroids | #119 |
| week 005 | #119 |
| 39 mmhg | #119 |
| skin elasticity | #119 |
| matter prevalence | #120 |
| syndromes epithelium | #120 |
| levels histamine | #121 |
| distance corrected | #121 |
| mitomycinc mmc | #121 |
| soft lenses | #121 |
| mitomycin ophthalmic | #121 |
| chronic allergic | #122 |
| titers ebv | #123 |
| collagen conjunctiva | #123 |
| male ointments | #123 |
| adult conjunctiva | #123 |
| artificial tear | #123 |
| area corneal | #124 |
| eosinophils cell | #124 |
| activity corneal | #125 |
| conjunctival tissues | #125 |
| damage severe | #126 |
| proteaseactivated receptor2 | #126 |
| month reduced | #126 |
| patients atopic | #127 |
| 05ng | #127 |
| nerves studied | #127 |
| subjects vivo | #127 |
| soft contact lenses | #128 |
| gamma increase | #128 |
| 9 genes | #128 |
| elisa levels | #129 |
| 361 ± | #129 |
| combination steroids | #129 |
| acds | #129 |
| fibroblast viability | #129 |
| fva | #130 |
| patients insignificant | #130 |
| functional visual | #130 |
| disease cornea | #131 |
| antigen hladr | #131 |
| cataract phacoemulsification | #132 |
| 5ac | #132 |
| eyes fluorescein | #132 |
| eye drop | #132 |
| management allergic | #132 |
| resection severe | #132 |
| treated tacrolimus | #133 |
| proteins mucin | #133 |
| gene transcription levels | #133 |
| 19 normal subjects | #133 |
| keratoplasty adult | #133 |
| skin water | #133 |
| surface examination | #134 |
| normal conjunctival | #134 |
| pcr hla | #134 |
| density negative | #134 |
| acrylic iol | #134 |
| specimens vivo | #135 |
| solutions phacoemulsification | #135 |
| stress status | #136 |
| iop treatment | #136 |
| ophthalmological dry | #137 |
| dry eye patients | #137 |
| ocular surface | #137 |
| antiallergic properties | #137 |
| severity 10 | #137 |
| eosinophil adhesion | #137 |
| eosinophil cationic protein | #138 |
| iol groups | #138 |
| asian dust storms | #138 |
| authors technique | #139 |
| allergic dogs | #139 |
| protein ecp | #139 |
| ratio remission | #139 |
| suppressed pretreatment | #140 |
| allergic patients | #141 |
| inflammation prostaglandin | #141 |
| aminobenzoates anti | #141 |
| interleukin1 interleukin13 | #142 |
| improvements symptom | #142 |
| findings upper | #142 |
| combination rapid | #143 |
| olopatadine hydrochloride | #143 |
| 52 mmhg | #144 |
| determine central | #144 |
| cornea cyclosporine | #144 |
| studies scleritis | #144 |
| eye syndromes | #145 |
| specimens patient | #145 |
| symptoms ocular | #145 |
| recordable | #145 |
| virus pathogen | #146 |
| underwent evaluation | #146 |
| reticular basement membrane | #146 |
| eye clinical | #146 |
| findings adolescent | #146 |
| schiff reaction | #146 |
| fibroblasts alpha | #146 |
| human conjunctiva | #146 |
| diagnosis atopic | #147 |
| required type | #147 |
| impression cytology | #147 |
| 263 years | #147 |
| hne 4 | #147 |
| dscg | #147 |
| 0001 corneal | #148 |
| dynamic visual acuity | #148 |
| increased goblet | #148 |
| ulcer drug | #148 |
| cationic protein | #149 |
| intraocular lens iol | #149 |
| quantitative evaluation | #149 |
| japan phenotype | #149 |
| suspension based | #149 |
| concentration tacrolimus | #149 |
| patients allergic | #149 |
| fibroblasts production | #149 |
| pyrimidinones treatment | #150 |
| inflammatory cells | #150 |
| japanese cedar pollen | #150 |
| inflammation reduction | #151 |
| controls performed | #151 |
| postoperative secondary | #152 |
| tacrolimus treated | #152 |
| par2 reverse | #152 |
| increased fibroblasts | #153 |
| artificial tears | #153 |
| symptoms objective | #153 |
| eyes 11 | #153 |
| induced eotaxin | #153 |
| 28 surgery | #153 |
| concentrations il4 | #154 |
| grade effects | #155 |
| inflammation ocular | #155 |
| male mitomycin | #155 |
| association pm25 | #156 |
| alcon | #156 |
| eyelids female | #156 |
| chemokine expression | #156 |
| rates untreated | #157 |
| lipid infiltration | #157 |
| ointments skin | #157 |
| inflammatory ocular | #157 |
| pcr increase | #157 |
| greater inflammation | #157 |
| values improved | #157 |
| analysis prostaglandin | #157 |
| acuities | #158 |
| japan included | #158 |
| surface status | #158 |
| trial tacrolimus | #158 |
| 3 boys | #159 |
| weeks adverse | #159 |
| immunological characteristics | #159 |
| study inflammation | #160 |
| muc16 | #161 |
| chemokines production | #161 |
| elevation study | #161 |
| mucin 5ac | #161 |
| 28 female | #161 |
| thirtysix eyes | #161 |
| acid schiff | #161 |
| surgery topical | #162 |
| bromobenzenes | #162 |
| 326 years | #162 |
| male meibomian | #162 |
| distance visual acuity | #162 |
| efficacy tacrolimus | #163 |
| visit 7 | #163 |
| olopatadine | #163 |
| studied 21 | #163 |
| twentynine eyes | #163 |
| il1beta il2 | #163 |
| prevalence ocular | #163 |
| oxidative stress status | #163 |
| steroid anti | #164 |
| 002 treatment | #164 |
| soft contact | #164 |
| 30ng | #164 |
| purpose reported | #164 |
| spt positive | #164 |
| patients topical | #164 |
| production prostaglandin | #165 |
| biological dressings | #165 |
| fluorescein humans | #166 |
| pgd2 induced | #166 |
| cytometry hla | #166 |
| tacrolimus ointment | #167 |
| eosinophils higher | #167 |
| cytokines allergic | #167 |
| ulcers erosions | #168 |
| males 5 | #168 |
| eotaxin chemokine | #169 |
| treating refractory | #169 |
| patients postsurgical | #169 |
| seldi | #169 |
| 12 males | #169 |
| studies tacrolimus | #169 |
| local allergic | #169 |
| steroidal blotting | #169 |
| expression chemokines | #170 |
| status inflammation | #171 |
| management enzyme | #171 |
| conjunctiva conjunctival | #171 |
| subbasal nerve | #172 |
| fibroblasts fibroblast | #173 |
| palisades | #173 |
| standard conventional | #174 |
| distance acuity | #174 |
| subjective symptoms | #174 |
| status oxidative | #174 |
| vivo confocal | #174 |
| slit lamp | #174 |
| pcr flow | #174 |
| 34 eyes | #175 |
| postkeratoplasty | #175 |
| homologous molecule | #176 |
| evaluated symptoms | #176 |
| treatment corneal | #177 |
| aldehydes biomarkers | #177 |
| subbasal | #177 |
| dust extract | #177 |
| study longterm outcomes | #177 |
| mild 2 | #178 |
| tryptase | #178 |
| strabismus adolescent | #178 |
| endophthalmitis female | #178 |
| reduction intraocular pressure | #178 |
| acrysof | #178 |
| risk ocular | #179 |
| chemokine genes | #179 |
| japan young adult | #180 |
| 4 female | #180 |
| ceramides child | #180 |
| dyes follow | #180 |
| migration eosinophils | #180 |
| compared eye | #180 |
| myopic regression | #180 |
| normal control patients | #181 |
| lipid study | #181 |
| cutometer | #181 |
| serum il4 | #183 |
| blepharitis | #183 |
| lipoproteins micafungin | #183 |
| male radioallergosorbent | #184 |
| human lymphocyte antigen | #185 |
| mucin4 mucins | #185 |
| igg virus | #185 |
| nerve prospective | #186 |
| therapy corneal | #186 |
| examined parameters | #186 |
| drug fibroblasts humans | #187 |
| corneal fibroblasts | #187 |
| efficacy topical | #187 |
| par2 mrna | #187 |
| atopic eosinophils | #187 |
| suspensions administration | #187 |
| 19 eyes | #188 |
| eye symptoms | #188 |
| il13 increased | #188 |
| corneal sensitivity | #188 |
| sensitivity regulation | #189 |
| allergic cross | #189 |
| production stromal | #189 |
| seconds patients | #189 |
| levels 33 | #190 |
| infiltrating eosinophils | #191 |
| tear break | #191 |
| assisted infrared | #191 |
| effects diesel | #191 |
| improvement subjective | #192 |
| allergic rhinoconjunctivitis | #193 |
| controls vivo | #193 |
| therapeutic study | #193 |
| 26 eyes | #194 |
| reactivation epstein | #195 |
| fibroblasts inhibited | #195 |
| expression rantes | #195 |
| female histamine | #196 |
| rigid gas | #196 |
| 80 allergens | #197 |
| methods primary | #197 |
| tear film stability | #197 |
| treatment topical | #197 |
| eyes 21 | #197 |
| interleukin4 production | #197 |
| tears time | #198 |
| combination topical | #198 |
| 28 eyes | #198 |
| elisa performed | #198 |
| effects topical | #199 |
| pollen prospective | #199 |
| perennial allergic | #201 |
| preservative free | #201 |
| pollen allergic | #201 |
| photorefractive keratectomy | #201 |
| mcp1 ip10 | #201 |
| receptor homologous | #202 |
| rsv infected | #202 |
| hypersensitivity interleukin13 | #202 |
| unit density | #202 |
| eosinophils neutrophils | #203 |
| grade scale | #204 |
| pge2 human | #204 |
| vcam1 icam1 | #204 |
| ova alum | #204 |
| differences iop | #204 |
| eyes 005 | #205 |
| inflammatory allergic | #205 |
| minutes 8 | #206 |
| time tbut | #206 |
| disease acd | #206 |
| disease dry | #206 |
| eyes cataract | #206 |
| count cornea | #207 |
| pressure lens | #207 |
| formation giant | #207 |
| ecp levels | #207 |
| glands middle | #207 |
| crth2 | #207 |
| size contact | #208 |
| mammalian milk | #208 |
| fluorescein fluorescent | #208 |
| tears aged | #208 |
| analysis pm25 | #209 |
| uncorrected corrected | #209 |
| human allergic | #210 |
| month reduction | #210 |
| treatment allergic | #210 |
| antiallergic drug | #211 |
| refractory conventional | #211 |
| oct diagnosis | #211 |
| tacrolimus combination | #212 |
| inflammation injection | #212 |
| iol patients | #212 |
| combination tests | #212 |
| conjunctiva eye | #213 |
| treated refractory | #213 |
| chamber anti | #213 |
| muc5ac | #214 |
| steroids treatment | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| allergic agents | #217 |
| conjunctival goblet | #217 |
| lens purpose | #218 |
| worse eyes | #218 |
| expressions higher | #219 |
| nuclear cataract | #219 |
| august october | #220 |
| metabolism lysine | #220 |
| conjunctival biopsy | #220 |
| tranilast | #220 |
| conjunctivitis acute | #221 |
| findings inflammation | #221 |
| level ambient | #222 |
| combined therapy | #222 |
| twentyfour eyes | #222 |
| cells crth2 | #222 |
| samples correlated | #222 |
| diseases dry | #222 |
| sensitivity measurements | #224 |
| 26 control subjects | #224 |
| symptoms short | #224 |
| iop corneal | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| eyes adult | #228 |
| treatment 3 months | #228 |
| corneal clarity | #228 |
| itching | #229 |
| followup cases | #229 |
| eye signs | #230 |
| corrected distance | #230 |
| treatment superior | #230 |
| 30 eyes | #231 |
| exhaust particles | #231 |
| activity eosinophils | #231 |
| scleral flap | #232 |
| alpha defensin | #232 |
| examined level | #232 |
| events initiation | #232 |
| anti allergic | #233 |
| cyclosporine treatment | #233 |
| proteinchip | #233 |
| 791 patients | #233 |
| concomitantly administered | #233 |
| dye staining | #233 |
| 644 years | #234 |
| cultured eosinophils | #235 |
| examined production | #235 |
| specimens patients | #236 |
| corneal disease | #236 |
| quantitatively evaluate | #236 |
| gamma transcripts | #237 |
| term topical | #237 |
| topical steroid | #238 |
| proliferative lesions | #240 |
| diagnostic abilities | #240 |
| tool quantitative | #240 |
| studied subjects | #240 |
| bf patients | #241 |
| eyes ocular | #241 |
| cromolyn sodium | #242 |
| cell chemotactic | #242 |
| surface lipid | #242 |
| common ocular | #245 |
| performed higher | #245 |
| specular microscopy | #246 |
| equivalent 2 | #247 |
| subjects males | #247 |
| eye drops | #247 |
| chemosis | #248 |
| specificity cutoff | #248 |
| failure visual | #250 |
| response prostaglandin | #251 |
| labeling intercellular | #251 |
| seasonal allergic | #252 |
| leukocyte child | #252 |
| males 13 | #252 |
| syndrome tears | #252 |
| subjective objective | #252 |
| levels tacrolimus | #253 |
| topical oral | #253 |
| corneal female | #255 |
| muc | #255 |
| improved vision | #255 |
| stability positive | #256 |
| dexamethasone inhibition | #256 |
| rantes expression | #256 |
| disease corneal | #257 |
| treating severe | #257 |
| eosinophil chemotaxis | #258 |
| questionnaire objective | #259 |
| tear | #259 |
| eosinophil infiltration | #260 |
| role histamine | #260 |
| additional medications | #260 |
| month treatment | #260 |
| eyes control | #260 |
| human transcription | #261 |
| expression rsv | #261 |
| h1 antagonist | #262 |
| smaller normal | #262 |
| severity adverse | #264 |
| immunohistochemistry increased | #264 |
| aged mucin | #264 |
| 1 month treatment | #264 |
| keratoplasty pkp | #265 |
| steroid induced | #265 |
| controls p0001 | #266 |
| eyelid diseases | #266 |
| signs blood | #267 |
| data weekly | #267 |
| microscopy negative | #268 |
| treatment atopic | #268 |
| respiratory syncytial virus | #268 |
| patients sjögren syndrome | #268 |
| studied production | #268 |
| sodium drug | #269 |
| h1 histamine | #270 |
| computer terminals | #270 |
| aged aldehyde | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| improved visual acuity | #273 |
| 13 males | #273 |
| aldose reductase inhibitor | #273 |
| combination eosinophils | #274 |
| epithelium endothelium | #274 |
| studies stevens | #274 |
| concentration quantitative | #274 |
| meibomian gland dysfunction | #275 |
| meibomian gland | #277 |
| tear breakup time | #277 |
| patients sjögren | #277 |
| grading score | #278 |
| individuals pcr | #278 |
| tbut | #278 |
| 13 females | #279 |
| eyes 14 | #279 |
| 0001 diagnosis | #279 |
| bloodaqueous barrier | #279 |
| multifunctional glycoprotein | #280 |
| interleukin il4 | #280 |
| required provide | #281 |
| 10 seconds | #281 |
| expressed th2 | #282 |
| disease purpose | #282 |
| cautery | #282 |
| gland dysfunction | #284 |
| ige positive | #284 |
| contralateral eye | #285 |
| amniotic membrane | #285 |
| atopic | #286 |
| seasons adolescent | #286 |
| th2 cytokines | #287 |
| layer adult | #288 |
| cases refractory | #288 |
| adult alkylating | #289 |
| study tacrolimus | #289 |
| entericcoated | #291 |
| eyedrops | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| treatment 01 | #294 |
| new antifungal | #294 |
| exponential equation | #294 |
| single therapy | #295 |
| levels ige | #295 |
| serum periostin | #295 |
| hyperemia | #297 |
| surgery statistically | #297 |
| seventy eyes | #299 |
| ccl11 chemokine | #300 |
| rose bengal | #300 |
| severity diagnosis | #300 |
| pkp | #301 |
| benzalkonium chloride | #301 |
| morphologic alterations | #302 |
| assessed based | #303 |
| cobblestone | #303 |
| moderate 3 | #303 |
| scanning laser | #304 |
| photophobia | #304 |
| scores worse | #305 |
| initiation treatment | #305 |
| operation patient | #305 |
| eczema severity | #306 |
| piperidines treatment | #306 |
| membrane patch | #307 |
| assessed 4 | #307 |
| gel application | #308 |
| interleukin13 interleukin2 | #309 |
| evaluation groups | #309 |
| 10 normal subjects | #309 |
| comfort level | #310 |
| inflammatory cell | #310 |
| compared simple | #310 |
| regard age | #311 |
| cytology specimens | #311 |
| slitlamp examination | #311 |
| treatment seasonal | #311 |
| 12 eyes | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| aged staining | #315 |
| eye adult | #315 |
| 19 normal | #316 |
| child corneal | #316 |
| interferometry light | #317 |
| cells cornea | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| dermatitis clinical | #320 |
| fluorophotometry | #320 |
| prospective singlearm study | #320 |
| cells chemotaxis | #321 |
| il8 rantes | #321 |
| ulcers | #323 |
| bilateral cataracts | #323 |
| agreement weighted | #324 |
| pollen allergen | #324 |
| eyes 19 | #325 |
| 15 30 minutes | #325 |
| 095 ± | #326 |
| icam1 vcam1 expression | #326 |
| chemokine concentrations | #327 |
| surgery diabetic | #327 |
| transplantation corneal | #328 |
| icam1 antibody | #329 |
| expression goblet | #329 |
| insensible | #330 |
| treatment 2 weeks | #331 |
| pressure ocular | #331 |
| dry eye disease | #332 |
| receptors il2r | #332 |
| leukocyte coculture | #333 |
| values daily | #335 |
| cornea diagnostic | #335 |
| eye treated | #335 |
| proprietary | #336 |
| corneal epithelial | #337 |
| 27 eyes | #337 |
| male staphylococcal | #337 |
| signs clinical | #339 |
| daily wear | #339 |
| eyes 27 | #341 |
| levels epithelial | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| corneal infection | #347 |
| measurements treatment | #347 |
| expression eosinophils | #348 |
| induced elevation | #348 |
| eyes 13 | #348 |
| test values | #350 |
| surgery eye | #350 |
| contrast visual | #352 |
| surface diseases | #352 |
| iop elevation | #353 |
| expression allergic | #354 |
| weekly average | #354 |
| temperature infrared | #355 |
| incidence allergic | #355 |
| choroidal detachment | #356 |
| examination serum | #356 |
| patients allergy | #357 |
| tear film | #357 |
| eyes 8 | #358 |
| local cytokine | #358 |
| tacrolimus tumor | #359 |
| months conventional | #359 |
| difference efficacy | #361 |
| subjects 13 | #361 |
| agents benzophenones | #362 |
| messenger blotting | #363 |
| aureus patients | #363 |
| injections lidocaine | #364 |
| function laser | #368 |
| studies sclera | #368 |
| treatment ocular | #368 |
| plant pollen | #368 |
| corneae male | #369 |
| eyes 17 | #370 |
| mucin1 mucin2 | #370 |
| postoperative adhesion | #370 |
| systemic control | #371 |
| cryptomeria japonica | #372 |
| inhibitors epithelium | #372 |
| sixteen eyes | #373 |
| micafungin middle | #374 |
| periodic acid schiff | #374 |
| assessment severe | #375 |
| cornea female | #375 |
| improvement local | #375 |
| extraction cell | #376 |
| retina tomograph | #376 |
| phacoemulsification prospective | #377 |
| levels atopic | #377 |
| higher human | #377 |
| 4 lower | #377 |
| 10 normal | #377 |
| treatment eyes | #378 |
| tarsal | #378 |
| count child | #378 |
| stimulation tnf | #380 |
| mitomycin | #380 |
| cornea eye | #381 |
| corneal inflammation | #381 |
| negative serum | #382 |
| pollinosis | #383 |
| inflammation epithelial | #383 |
| gas permeable | #384 |
| examinations including | #384 |
| vivo corneal | #385 |
| ocular diseases | #386 |
| corneal epithelial cells | #386 |
| surgery 13 | #388 |
| limit assay | #388 |
| decrease inflammatory | #388 |
| surface alterations | #388 |
| healing adult | #389 |
| cells vehicle | #389 |
| sde | #390 |
| severity incidence | #390 |
| antiallergic | #391 |
| patients proteins | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| chronic ocular | #395 |
| applied 5 | #395 |
| 44 eyes | #395 |
| relative percentages | #396 |
| opacity corneal | #396 |
| techniques interleukin4 | #396 |
| expression lower | #397 |
| apparatus lacrimal | #397 |
| increased understanding | #398 |
| ocular surface disease | #399 |
| pressure elevation | #399 |
| declaration helsinki | #400 |
| remission based | #400 |
| eyes severe | #401 |
| modified boyden | #401 |
| rays male | #402 |
| sedating humans | #403 |
| measurements oct | #404 |
| cells allergic | #404 |
| vogt | #404 |
| weather air | #404 |
| prospective controlled study | #405 |
| patients epithelial | #406 |
| reproducibility surface | #406 |
| 137 years | #407 |
| serum total ige | #407 |
| improved diagnosis | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| eyes 15 | #412 |
| acids fibroblasts | #412 |
| specific total | #412 |
| confocal | #412 |
| counts 1 | #413 |
| 3 months treatment | #413 |
| allergic reaction | #413 |
| keratocytes | #414 |
| limbal | #416 |
| postoperative inflammation | #416 |
| central cornea | #418 |
| penetrating keratoplasty | #418 |
| patients comfort | #419 |
| mucin4 | #419 |
| speed resolution | #419 |
| chemokine ccl11 | #419 |
| ophthalmologist | #420 |
| sjögren syndrome | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| clinical observation | #425 |
| 40 minutes | #425 |
| production 4 | #430 |
| trabeculectomy visual | #430 |
| rhinoconjunctivitis | #431 |
| staining score | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| cedrus | #437 |
| performed immunohistochemistry | #437 |
| methods eye | #438 |
| regulation eye | #438 |
| 5 women | #438 |
| commercial tests | #439 |
| interleukin4 il4 | #440 |
| subjects studied | #440 |
| foldable | #440 |
| vmr | #441 |
| fluorescein dye | #441 |
| landolt | #441 |
| regulation chemokine | #441 |
| females normal | #442 |
| adult aldehydes | #442 |
| anti vcam1 | #442 |
| 17 males | #444 |
| male mucin1 | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| dogs dust | #448 |
| air pollution data | #448 |
| male 4 | #450 |
| 30 serum | #450 |
| eye eyes | #451 |
| keratoplasty | #452 |
| wash | #452 |
| ketotifen | #453 |
| versus vehicle | #453 |
| antagonists sedating | #453 |
| vivo confocal microscopy | #454 |
| normal patients | #454 |
| response allergens | #454 |
| surface disorder | #454 |
| water evaporation | #455 |
| 8 genes | #455 |
| ophthalmic nerve | #455 |
| production clearance | #455 |
| humans keratoplasty | #456 |
| agonists pilocarpine | #456 |
| normal controls patients | #457 |
| outpatient visits | #457 |
| ocular risk | #457 |
| amnion cell | #457 |
| checker | #459 |
| oct study | #460 |
| greatest improvements | #461 |
| distance visual | #461 |
| keratoplasty penetrating | #462 |
| test evaluation | #462 |
| hel | #466 |
| unpaired ttest | #467 |
| fibroblasts tgf | #467 |
| study pcr | #468 |
| background atopic | #469 |
| examination diagnosis | #469 |
| major sources | #470 |
| markers severity | #473 |
| allergy adult | #473 |
| metry | #475 |
| hladr expression | #476 |
| diagnosis rate | #476 |
| pollen seasons | #478 |
| 13 mmhg | #478 |
| fibroblasts primary | #478 |
| reduce clinical | #480 |
| height measurement | #480 |
| newly formed vessels | #480 |
| subjects eyes | #481 |
| examined prospective | #482 |
| interleukin 13 | #482 |
| crystalline lens implantation | #485 |
| 21 eyes | #488 |
| accommodating | #488 |
| induced 15 | #489 |
| shortterm study | #490 |
| myopia photorefractive | #490 |
| disodium cromoglycate | #493 |
| prolonged inflammation | #495 |
| ebv reactivation | #495 |
| acuity intraocular | #495 |
| months eyes | #498 |
| corneal | #498 |
| stain positive | #499 |
| il2 tumor | #499 |
| exposure diesel | #499 |
| silicone hydrogel | #500 |
| lens iol | #500 |
| infections viral | #501 |
| symptoms efficacy | #501 |
| studies status | #502 |
| treatment eye | #502 |
| pge2 cox2 | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| 2 daily | #505 |
| eye position | #505 |
| airborne particulate matter | #506 |
| correlate severity | #506 |
| inflammatory status | #506 |
| penetrating male | #507 |
| induced ocular | #509 |
| aldose reductase | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| topical | #516 |
| 45 subjects | #516 |
| disposable equipment | #517 |
| male water | #519 |
| inhibition production | #519 |
| observed baseline | #519 |
| groups duration | #520 |
| lipopeptides lipoproteins | #520 |
| 01 | #522 |
| chemoattractant receptor | #522 |
| metaregression analysis | #523 |
| infection rsv | #524 |
| 10 normal volunteers | #524 |
| studies trabeculectomy | #525 |
| dinoprostone epithelial | #525 |
| studies cornea | #527 |
| trabeculectomy | #527 |
| density basal | #528 |
| giemsa staining | #528 |
| rhodanine | #531 |
| itchy | #531 |
| serum antigen | #535 |
| ocular symptoms | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| total hydrocarbons | #538 |
| patients cataract | #538 |
| dependent migration | #539 |
| sac | #539 |
| capsular bag | #540 |
| placebo tablets | #540 |
| 80 anterior | #541 |
| visit 6 | #541 |
| cases flow | #542 |
| administration topical | #542 |
| infrared radiation | #543 |
| 20 normal | #543 |
| 6 male | #544 |
| production cultured | #546 |
| ebv nuclear antigen | #546 |
| time improved | #547 |
| periodic acid | #549 |
| pollution allergens | #549 |
| prospective comparative study | #550 |
| film layer | #550 |
| il‐4 | #552 |
| cryptomeria | #552 |
| disease complicated | #553 |
| effects cooling | #553 |
| engorgement | #554 |
| genechip | #555 |
| fibroblasts response | #555 |
| disease ded | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| density assessed | #558 |
| transplantation combined | #558 |
| methods thirty | #559 |
| diesel exhaust particles | #559 |
| ocular infections | #560 |
| differentiation inflammatory | #560 |
| eyes iop | #560 |
| eyes 24 | #562 |
| laser trabeculoplasty | #562 |
| positive 30 | #563 |
| count corneal | #569 |
| 16 age | #569 |
| levels il4 | #570 |
| cultured corneal | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| 4 mrna | #580 |
| iop eyes | #580 |
| apparatus male | #582 |
| lesions normal | #582 |
| fibrosis fluorescent | #582 |
| increase vegf | #584 |
| department ophthalmology | #584 |
| tnfalpha stimulation | #584 |
| symptoms scores | #588 |
| patients csa | #589 |
| intraocular male | #589 |
| female humans allergic | #589 |
| induced 4 | #589 |
| corneal epithelium | #589 |
| hladr antigen | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| assay eye | #597 |
| findings evaluated | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| inflammation status | #609 |
| topical adult | #609 |
| corneal nerves | #611 |
| thermography | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| antagonists humans | #615 |
| patients complained | #615 |
| diagnosis type | #616 |
| cells oligopeptides | #616 |
| ocular allergy | #617 |
| grades 0 | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| lamp examination | #625 |
| glaucoma medications | #625 |
| years studied | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| redness | #636 |
| corneal haze | #636 |
| patients tacrolimus | #636 |
| burning sensation | #636 |
| total immunoglobulin | #638 |
| based severity | #639 |
| eosinophils | #639 |
| contact lenses | #639 |
| male rhinitis | #640 |
| 511 patients | #640 |
| 11 eyes | #641 |
| development allergic | #641 |
| symptoms signs | #643 |
| months 01 | #643 |
| performed modified | #643 |
| observed follow | #644 |
| fibrosis actins | #645 |
| mellitus double | #645 |
| patients healthy volunteers | #650 |
| expression administration | #651 |
| 2 females | #651 |
| viscosupplements | #651 |
| eosinophils flow | #654 |
| analysis existence | #654 |
| diseases methods | #656 |
| lacrimal | #657 |
| comfortable | #657 |
| patients elisa | #660 |
| 96well plate | #661 |
| nerve density | #661 |
| chamber technique | #662 |
| lens wearers | #664 |
| treatment 0001 | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| viruses acute | #669 |
| 10 age | #669 |
| damage scores | #669 |
| cedar | #672 |
| stimulation rna | #672 |
| 11 males | #673 |
| humans lacrimal | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| test methods | #681 |
| adherence anti | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| fibronectin cell | #684 |
| stainings | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| cells eye | #694 |
| atopic female humans | #694 |
| 1 test | #695 |
| inhibition expression | #697 |
| early antigen | #697 |
| objective assessments | #700 |
| cromolyn | #700 |
| levels detection | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| fibroblasts flow | #715 |
| 1 month | #715 |
| major characteristic | #717 |
| key cells | #718 |
| 5 eyes | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 088 ± | #724 |
| 32 eyes | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| followup treatment | #730 |
| aged ophthalmology | #730 |
| 11 male | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| reductase inhibitor | #737 |
| symptoms 5 | #737 |
| intraocular lens | #740 |
| density compared | #741 |
| keratectomy | #741 |
| expression real | #744 |
| blood eosinophils | #746 |
| definition classification | #746 |
| unpaired test | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| cornea corneal | #751 |
| daily weather | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| iol implantation | #759 |
| follow cases | #759 |
| allergens anti | #762 |
| trabeculectomy treatment | #763 |
| intraocular lens implantation | #763 |
| topical aged | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| oligopeptides rna | #769 |
| pathogenesis severe | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| levels prostaglandin | #783 |
| role allergic | #783 |
| fluorescein fluoresceins | #784 |
| limbus corneae | #784 |
| blinking | #785 |
| treatment 1 | #785 |
| purpose analyze | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| eyes normal | #792 |
| lenses intraocular | #792 |
| techniques laminin | #793 |
| tacrolimus | #793 |
| increased epithelial | #793 |
| ocular inflammation | #794 |
| 4 hne | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| report efficacy | #801 |
| positive linear | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| mucin | #813 |
| receptors ccr3 | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| concentration dose | #820 |
| aged cell | #820 |
| cells eosinophils | #821 |
| interleukin4 | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| preoperative level | #834 |
| lymphocytes compared | #834 |
| cases follow | #835 |
| surgical outcome | #835 |
| pachymetry | #840 |
| individuals patients | #841 |
| patients operation | #841 |
| implantation intraocular | #842 |
| ocular adolescent | #843 |
| symptoms improved | #843 |
| elevated iop | #845 |
| new surgical technique | #845 |
| exhaust | #848 |
| levels air | #848 |
| 2 weeks treatment | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| purpose prospectively | #855 |
| cell area | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| myopic eyes | #861 |
| inhibitors diclofenac | #861 |
| thiazolidines | #865 |
| histamine h1 | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| patients eyes | #874 |
| 01 compared | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| evaluation early | #880 |
| benzamidine | #880 |
| h1 antagonists | #880 |
| patient comfort | #881 |
| cells contributes | #882 |
| assessing efficacy | #882 |
| diseases background | #883 |
| study eye | #886 |
| bleb | #887 |
| patients condition | #887 |
| specular | #890 |
| respiratory syncytial | #894 |
| 114 years | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| benzophenones | #905 |
| decreased baseline | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| examined pcr | #911 |
| lacrimal duct | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| 8 males | #928 |
| treatment symptoms | #928 |
| immunoregulatory effects | #929 |
| epithelial lesions | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| normal controls | #933 |
| ophthalmologic surgical | #933 |
| epithelialization | #937 |
| beta1 tumor | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| cytokines epithelial | #941 |
| symptoms evaluated | #941 |
| normal 1 | #943 |
| factor production | #946 |
| humans muscarinic | #946 |
| wheal | #947 |
| radioallergosorbent test | #949 |
| mgd | #949 |
| humans lenses | #950 |
| seasons young | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| 2 moderate | #957 |
| scanning confocal | #957 |
| 3 eyes | #959 |
| aldose | #959 |
| singleagent therapy | #959 |
| endpoint baseline | #960 |
| sedating | #961 |
| intracellular infection | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| basal epithelial | #973 |
| term therapeutic | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| observed conclusions | #994 |
| tenon | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| observed vivo | #1002 |
| methods sixteen | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| time year | #1012 |
| eye infections | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| 1 2 weeks | #1017 |
| blink | #1017 |
| impression | #1019 |
| normal volunteers | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| patching | #1040 |
| webbased questionnaire | #1040 |
| 045 ± | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| cells fibroblasts | #1044 |
| lysine 4 | #1044 |
| concomitantly | #1045 |
| treatment skin | #1045 |
| xerophthalmia | #1046 |
| recurrence 6 | #1050 |
| indirect humans | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| pollution risk | #1067 |
| staphylococcal enterotoxin | #1067 |
| disposable | #1067 |
| noninfectious | #1070 |
| acuity patients | #1071 |
| goblet cell | #1071 |
| immunocytochemical study | #1073 |
| effective treating | #1075 |
| months corrected | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| syncytial virus | #1080 |
| ade | #1080 |
| techniques ophthalmological | #1080 |
| allergic inflammatory | #1082 |
| expression icam1 | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| diseases objective | #1104 |
| assessed vivo | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| rose | #1116 |
| lens capsule | #1116 |
| 30 patients | #1118 |
| keratopathy | #1121 |
| drops | #1121 |
| popularization | #1122 |
| 92 years | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| cultures human | #1133 |
| assay fibroblasts | #1133 |
| treatment objective | #1133 |
| clinical findings | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| healthy eyes | #1140 |
| visual acuities | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| 4 daily | #1146 |
| p0035 | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| sjögrens syndrome | #1171 |
| purpose evaluate | #1171 |
| glands sjogren | #1173 |
| cornea | #1173 |
| ophthalmological female | #1189 |
| fibronectins fibrosis | #1189 |
| immune mechanisms | #1189 |
| levels chemokines | #1191 |
| adult dermatitis | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| 84 ± | #1210 |
| concentrations alpha | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| study eyes | #1286 |
| aged substance | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| chemokines chemotaxis | #1316 |
| higher severe | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| expressed secreted | #1321 |
| child chromatography | #1321 |
| ccl11 | #1322 |
| 830 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| 18 eyes | #1399 |
| female glucocorticoids | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| proteaseactivated receptor | #1413 |
| diseases diagnosis | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| corneal neovascularization | #1444 |
| haze | #1444 |
| temperature cell | #1445 |
| goblet cells | #1451 |
| reduced 1 | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| western cells | #1499 |
| detected frequently | #1499 |
| male metaplasia | #1500 |
| studies suture | #1502 |
| bulbar | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| staining | #1514 |
| female fluorescein | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| ortho aminobenzoates | #1602 |
| preservative | #1602 |
| cells 0001 | #1603 |
| vdt | #1624 |
| humans intraocular | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| syncytial | #1663 |
| 10 healthy controls | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| disease defined | #1713 |
| outcome visual | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| central corneal | #1741 |
| cytology | #1741 |
| treatment short | #1742 |
| severity treatment | #1754 |
| years 19 | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| receptor par2 | #1823 |
| japan methods | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| 15 minutes | #1828 |
| eosinophil | #1828 |
| child dermatitis | #1832 |
| mediator release | #1835 |
| epithelial damage | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| comparative evaluation | #1860 |
| shield | #1860 |
| tnfalpha production | #1862 |
| ari | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| aphakia | #1893 |
| cataract surgery | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| severe persistent | #1946 |
| protein female | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 9 males | #1970 |
| 5 minutes | #1970 |
| 4 males | #1971 |
| device treatment | #1972 |
| comfort | #1972 |
| corrected visual | #1974 |
| gpc | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| tacrolimus adult | #2023 |
| agents male | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| coherence treatment | #2038 |
| treated eyes | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| allergens animals | #2067 |
| ambient air pollution | #2067 |
| versus normal | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| docosahexaenoic acid | #2137 |
| endopeptidases serine | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| production inhibited | #2164 |
| curve reproducibility | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| diseases female | #2192 |
| aged mitomycin | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| rater agreement | #2246 |
| vital | #2246 |
| scores correlated | #2247 |
| pollens | #2247 |
| groups difference | #2250 |
| allergic seasonal | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| clinical appearance | #2312 |
| topical treatment | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| ophthalmology | #2415 |
| aged nitrogen | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| fungal female | #2498 |
| enteric coated | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| methods clinical | #2571 |
| oct | #2571 |
| male polymerase | #2573 |
| flare | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| eosinophilia female | #2629 |
| postsurgical | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| bf | #2698 |
| tearing | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| matched normal | #2772 |
| total ige | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| atopic dermatitis | #2821 |
| higher cases | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| anterior chamber | #2907 |
| test performed | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| eosinophils humans | #3014 |
| measured elisa | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| rtpcr | #3132 |
| expression adhesion | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| cell count | #3181 |
| symptom scores | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| vegf mrna | #3694 |
| disease adolescent | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| suture techniques | #3751 |
| adult air | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| management disease | #3773 |
| helper type | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| chemokines | #3992 |
| microscopy | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| α induced | #4193 |
| papillary | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| nitrogen dioxide | #5023 |
| months treatment | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| thirtysix patients | #5224 |
| epithelium | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| grades | #5747 |
| th2 cells | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| rejection humans | #6543 |
| house dust | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| linked immunosorbent | #6618 |
| glucocorticoids humans | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| months compared | #6704 |
| humans japan | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| complaints | #9098 |
| 3 6 | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| epithelia | #13267 |
| 4 weeks | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| stained | #18391 |
| alkylating | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
Open the FULL List in Excel | |
Prominent publications by Hiroshi Fujishima
KOL-Index: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| Known for Ocular Surface | Eyes Corneal Ulcers | Atopic Patients | Brush Cytology | Akc Vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| Known for Dry Eye Disease | Coherence Tomography | Tear Meniscus Height | Sensitivity Specificity | Strip Meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| Known for Oxidative Stress | Akc Patients | Surface Disease | Inflammatory Cells | 5 Females |
KOL-Index: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| Known for Vkc Akc | Allergic Conjunctivitis | Topical Steroids | 1 Month | Objective Signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| Known for Atopic Keratoconjunctivitis | Ocular Surface | Patients Akc | Muc5ac Muc16 | Goblet Cell |
KOL-Index: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| Known for Ocular Surface | Atopic Keratoconjunctivitis | Patients Akc | Eyes Vkc | Brush Cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| Known for Atopic Keratoconjunctivitis | Ocular Surface | Brush Cytology | Corneal Sensitivity | Epithelial Mucins |
KOL-Index: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| Known for Intraocular Lens | Visual Acuity | 1cu Iol | Cataract Surgery | Amplitude Accommodation |
KOL-Index: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| Known for Receptor Crth2 | Chemotaxis Eosinophils | Allergic Conjunctivitis | Pgd2dependent Migration | Homologous Molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| Known for Severe Allergic Conjunctivitis | Tacrolimus Ophthalmic | Objective Signs | Corneal Involvement | Clinical Trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| Known for Conjunctival Fibroblasts | Vascular Endothelial | Growth Factor | Vegf Concentration | Akc Vkc |
KOL-Index: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| Known for Intraocular Lens | Thinoptx Iol | Phacoemulsification Implantation | Visual Acuity | 6 Months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| Known for Ocular Surface | Topical Cyclosporine | Eye Patients | Chronic Graft | Host Disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| Known for Allergic Conjunctivitis | Tears Patients | Vkc Gpc | Normal Controls | Linked Immunosorbent |
Key People For Allergic Conjunctivitis
Top KOLs in the world
Hiroshi Fujishima:Expert Impact
Concepts for whichHiroshi Fujishimahas direct influence:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:KOL impact
Concepts related to the work of other authors for whichfor which Hiroshi Fujishima has influence:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |